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ABSTRACT 
 
Bin-Jin Hwang: The hemidesmosomal protein BP180 (collagen XVII) in skin cancer  
and inflammation 
(Under the direction of Zhi Liu) 
 
 
BP180, also known as collagen XVII, is a transmembrane glycoprotein located in 
the hemidesmosome of basal keratinocytes, and functions as a key cell-matrix adhesion 
molecule. Loss of BP180 function in human disease leads to subepidermal blistering, 
and can occur by either autoantibody production (bullous pemphigoid) or inherited 
mutations in the BP180 gene COL17A1 (junctional epidermolysis bullosa). However, its 
other biological functions and involvement in different pathological conditions are 
unknown. To uncover new functions of BP180, we generated a novel BP180 
dysfunctional mouse strain lacking the NC16A domain of BP180 (termed ∆NC16A). We 
found that ∆NC16A mice developed a proinflammatory microenvironment in the skin 
accompanied by an influx of immune cells, including mast cells and MDSCs. ΔNC16A 
mice show spontaneous skin inflammation accompanied by TSLP-dependent itch. 
When tested in the B16 mouse melanoma models, ∆NC16A mice showed significantly 
increased melanoma progression. NC16A deletion in the skin or epidermis was 
sufficient to promote skin inflammation and tumor progression, demonstrating that 
BP180 dysfunction in basal keratinocytes is responsible for the proinflammatory 
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microenvironment and increased tumor progression. Mast cell-deficient ∆NC16A mice 
had drastically reduced MDSCs in the skin and developed significantly reduced 
melanoma. Mast cell reconstitution restored the skin infiltration of MDSCs and 
increased melanoma progression in mast cell-deficient ∆NC16A mice. More importantly, 
MDSC depletion significantly reduced the tumor progression in mast cell-sufficient 
∆NC16A mice. These findings provide the first evidence suggesting that BP180 in basal 
keratinocytes, as a hemidesmosomal cell-cell matrix adhesion protein, plays a vital role 
in skin inflammation and melanoma progression. 
iii 
 
ACKNOWLEDGEMENT 
 
I would like to thank Dr. Zhi Liu for his mentorship and support during the past six 
and a half years. It is my greatest honor to work in this lab. I would like to thank every 
member in my committee for their guidance over the past years. Without Dr. Maureen 
Su’s expertise in tumor immunology, my melanoma project probably would not have 
progressed as smoothly as it did. Dr. Scott Williams provided me the valuable training 
and materials to generate stabilized primary keratinocyte cultures, which proved to be 
critical in my projects. I would like to thank Dr. Jenny Ting and Dr. Yisong Wan for their 
comments and suggestions on my project.  
 
I would also like to give my gratitude to Dr. Robert Bourret for his tremendous 
support during my years in the Department of Microbiology and Immunology.   
 
Also, I would like to thank everyone in the Department of Dermatology, especially 
for their wonderful advice and assistance during the past years. Even though Dr. Li is 
not a member in my committee, she still provided extremely valuable guidance for the 
past years in my projects. Susan McCray provided me the best training and assistance 
in flow cytometry I can get at UNC. Also, I would like to thank the pathology core in the 
Department of Dermatology, especially Dr. Greg Sturtz for his wonderful assistance. I 
would like to thank Phillip S Prisayanh, for so much wonderful support in the lab. I would 
iv 
 
like to thank to Dr. Donna Culton, Dr. Ye Qian, our current chair Dr. Nancy Thomas and 
the former chair Dr. Luis A Diaz. They are wonderful to work with and my work could 
have not been done without the full support of the UNC Department of Dermatology.  
 
In addition, I am thankful to all the current and past members of the Liu Lab, it 
has been great to work with you all. Most especially to my graduate school “elder-sister” 
Dr. Lan Lin, who has been a wonderful friend and listener. Without her assistance for 
the past years, my life as a graduate student will be much more miserable. I also want 
to thank all the other graduate students and research assistants who worked with me in 
Dr. Liu’s lab one by one. I want to give my special thanks to Susan W Burette, for her 
help as the most wonderful lab manager in the lab. Dr. Lin Lin is really a wonderful lab 
mate for the past years. Jaime Brozowski first found that B16 melanoma progression is 
significantly increased in our BP180 dysfunctional mice with help from Dr. Maureen Su, 
which paved the way for my dissertational research, in which I owe her a lot. I sincerely 
wish her good fortune in finishing her PhD degree in Dr. Tarrant’s lab. Dr. Flor de María 
Evangelista Montoya, Dr. Lisa Heimbach, Kayla Schumate and Ryan Collins have been 
wonderful lab mates to work with. I would like to thank to all the exchange graduate 
students and visiting scholars in Dr. Liu’s lab one by one. It is really my honor to work 
with Dr. Zhen Liu and Dr. Yang Zhang on the itch/skin inflammation project. I also want 
to acknowledge Dr. Jinbo Chen, who taught me a lot in developing my dissertation 
research project and skin histology. I also would like to thank to Dr. Bin Peng and Dr. 
Peng Geng, who are wonderful listeners for the past years.  
 
v 
 
In addition, I thank deeply UNC Graduate School and the American Association 
of Immunologists. I would like to thank UNC Graduate School for awarding me with the 
Dissertation Completion Fellowship, which supported me for a year financially. In 
addition, it was my greatest honor to receive the Young Investigator Award from the 
American Association of Immunologists at the Southeastern Immunology Symposium, 
2016.  
vi 
 
TABLE OF CONTENTS 
LIST OF FIGURES…………………………………………………………………………....VIII 
LIST OF TABLES………………………………………………………………………….....XIII 
LIST OF ABBREVIATIONS……………………………………………………………….....XIV 
CHAPTER 1 BACKGROUND……………………………………………………………...….1 
1.1 BP180 and the hemidesmosome…………………………………………………..1 
1.2 Skin inflammatory diseases and BP180…………………………………….…….3 
1.2.1 Autoimmune Bullous Pemphigoid…………………………………….....3 
1.2.2 Junctional Epidermolysis Bullosa (JEB) ………………………………..4 
1.2.3 The possible correlation between BP180  
dysfunction and skin inflammation.…….……….……………………….6 
 
1.3 Inflammation, myeloid-derived suppressor cells (MDSCs),  
mast cells and cancer / melanoma progression.…………………………………7 
 
1.3.1 Inflammation and Cancer……………,,,…………………………………7 
1.3.2 Myeloid-Derived Suppressor Cells (MDSCs) ………………………...11 
1.3.3 Mast Cells.………………………………………………………….…….14 
1.4 Known correlation between altered expression of BP180  
and skin cancers.…………………………………………………………………..15 
 
1.5 Mouse model for BP180 physiological functions.………………………..……..16 
1.6 Working hypothesis for my dissertation…………………………………………..18 
1.7 References.……………………………………………………………....................19
vi 
 
CHAPTER 2 THE DYSFUNCTION OF BP180/COLLAGEN XVII  
IN KERATINOCYTES LEADS TO MAST CELL-DEPENDENT 
 SKIN INFILTRATION OF MYELOID DERIVED SUPPRESSOR 
 CELLS AND ACCELERATED MELANOMA PROGRESSION……………………..…..27     
 
2.1 Overview and Significance….…,,,……………….…………………...................28 
2.2 Introduction……………………………………………........................................29 
2.3 Results….………...………………………………...............................................32 
2.4 Discussion……...………………..………………………………..........................40 
2.5 References….……………………......................................................................71 
CHAPTER 3 BP180 DYSFUNCTION TRIGGERS SPONTANEOUS  
SKIN INFLAMMATION IN MICE…………………………………………………………….76 
 
        3.1 Overview and Significance…...………………………………………...................76 
        3.2 Introduction….……………………………………….…........................................78 
         3.3 Results….…………………………………………...............................................80 
         3.4 Discussion….………………………………………….........................................88 
         3.5 Materials and Methods….……………………………………….......................93 
         3.6 References….…………………………………………......................................118 
CHAPTER 4 DISCUSSION AND FUTURE DIRECTIONS……………………………123 
         4.1 Summary and Findings….…………………………………………....................123 
         4.2 New understandings of BP180 in skin inflammation……………………….….125 
vii 
 
         4.3 New Function of BP180 in melanoma progression  
               through skin basal  keratinocytes……………………………..…………………128 
 
        4.4 Possible roles of BP180 in modulating the proinflammatory  
              signaling pathway in keratinocytes, which leads to skin  
              inflammation and melanoma progression. ……………………..………………132 
 
        4.5 Proposed future experiments………………………..……………………………137 
        4.6 References…………………………………………..……………………………..142 
viii 
 
LIST OF FIGURES 
1.1 The structure of BP180 protein………………………………………………………….2 
1.2 Epidermolysis bullosa (EB)..…………………………………………………………….5 
1.3 Types of Inflammation in cancer progression. ………………………………………..9 
2.1. BP180 dysfunction ΔNC16A mice develop spontaneous  
       skin inflammation……………………………………………………….………………...50 
 
2.2. ΔNC16A mice show significantly increased melanoma  
       progression in both flank and ear injection models………..………………………….52 
 
2.3. Skin- and basal keratinocyte-specific BP180 dysfunction  
       are sufficient to promote B16 melanoma progression. ……….……………………...54 
 
2.4. Mast cells are crucial for melanoma progression in  
       ∆NC16A mice……………………………………………………………………………..56 
 
2.5. Whole body-, skin- and basal keratinocyte-specific  
       ΔNC16A mice have increased infiltration of MDSCs  
       in the skin…………………………………………………………………………...……..58 
 
2.6. Mast cells and MDSCs are crucial for MDSC infiltration  
       in ∆NC16A mice………………………………………,,,…………………………….….60 
 
2.7. BP180 dysfunction in skin basal keratinocytes triggers  
       MC infiltration into skin, which leads to MDSC promoted  
       melanoma progression……………….…………………………..……………………...62 
ix 
 
 
S2.1. Generation of skin-specific ΔNC16A mice…………………………………………...63 
S2.2. Skin-specific ΔNC16A is sufficient to promote skin  
          inflammation……………………………………………………………………..……...64 
 
S2.3. Myeloperoxidase (MPO) results indicate that ΔNC16A  
          promotes the influx of myeloid cells into skin………………..………………………65 
 
S2.4. ΔNC16A leads to the upregulation of proinflammatory  
         cytokines in skin…………………………….………………………………………..…66 
 
S2.5. Generation of basal keratinocyte conditional  
          K14Cre/ΔNC16A mice……………………………….……………………………..….67 
 
S2.6. Anti-Gr1 antibody mediated myeloid cell depletion  
         significantly reduces Gr1 positive immune cells in the  
         skin of ΔNC16A mice…………………………………………………………..……....68 
 
3.1. ΔNC16A mice exhibit skin inflammation with itch…………………………………..100 
3.2. Skin-specific ΔNC16A (SkinΔNC16A) mice develop skin  
       inflammation with increased immune cell infiltration,  
       increased epidermal thickness, itch, serum IgE and TSLP…………..………….…102 
 
3.3. Basal keratinocyte-specific ΔNC16A (K14Cre/ΔNC16A) 
       mice exhibit skin inflammation………………..……………………………………….104 
 
3.4. ΔNC16A mice deficient in both T and B cells  
       (Rag1-/-ΔNC16A) develop similar skin inflammation  
x 
 
       as whole body ΔNC16A mice…………………………………………………….……105 
 
3.5. Itch in ΔNC16A mice is independent of IgE and histamine, 
       but dependent on TSLP in keratinocytes…………………………………..………...106 
 
S3.1. ΔNC16A mice exhibit skin inflammation with itch………………………………….108 
S3.2. ΔNC16A mice exhibit increased immune cell infiltration…………………………109 
S3.3. Quantification of cytokines at mRNA levels……………………………………..…110 
S3.4. Generation of skin-specific ΔNC16A (skinΔNC16A) mice. ……………………...111 
S3.5. Skin ΔNC16A mice exhibit increased immune cell  
          infiltration and a defective skin barrier……………….….……………………….....112 
 
S3.6. Basal keratinocyte-specific ΔNC16A (K14Cre/ΔNC16A)  
         mice exhibit skin inflammation………………..……..…………………………….....113 
 
S3.7. ΔNC16A mice deficient in both T and B cells  
        (Rag1-/-ΔNC16A) develop similar skin inflammation as  
        whole body ΔNC16A mice...………….……………................................................114 
 
S3.8. B cell-deficient ΔNC16A mice develop skin inflammation………………………...115 
4.1. Summary and conclusion of my past research covered  
       at Chapter 2 and 3………………………………………………………………………125 
 
4.2 CXCR2 deficiency did not significantly reduce the tumor  
      progression in ΔNC16A mice.………………………………….……………..………..131 
 
xi 
 
4.3 Mast cells play a significant role in the concentration of  
      CCL2 and CXCL1 in ∆NC16A mice…………………………..…………….………....133 
 
4.4. Keratinocytes lacking NC16A promote the production of  
       CXCL1 through NF-κB……………………………………………………………….…135 
 
4.5. ∆NC16A significantly upregulates the phosphorylation  
       of FAK in vitro………………………………………………...………………..…….….136 
 
4.6. FAK and Src inhibition significantly reduce the increased  
       CXCL1 production in ∆NC16A keratinocytes………………………….……………..136 
 
4.7. Two future experiments I proposed………………………….…………..……………138 
4.8. NF-κB inhibitor ammonium pyrrolidinedithiocarbamate  
       (PDTC) significantly reduces the level of stem cell factor  
       (SCF) in the skin of ∆NC16A mice…………………………...…………..…….……..140
xiii 
 
LIST OF TABLES 
Table 
2.1. The NC16A KO mice showed an increased expression 
        of proinflammatory cytokines and chemokines which are  
        associated with the proinflammatory tumor microenvironment……………..……...69 
 
3.1. Increased expression of proinflammatory cytokines in 
        ΔNC16A mice. Skin RNA was isolated from three age and sex  
        matched NC16A (WT) and ΔNC16A (KO) mice (8 weeks old),  
        and was used for whole transcriptome microarray analysis.  
        increased expression of proinflammatory cytokines and  
        chemokines associated with dermatitis is listed. .……………..……………………116 
  
  
xiv 
 
LIST OF ABBREVIATIONS 
AD: atopic dermatitis 
BCC: basal cell carcinoma 
BMZ: basement membrane zone 
BP: Bullous Pemphigoid 
BSA: bovine serum albumin 
FITC: fluorescein isothiocyanate 
H1R: histamine 1 receptor 
H4R: histamine 4 receptor 
IB: immunoblotting 
IF: immunofluorescence 
IFNγ: interferon γ 
IL: interleukin 
JEB: junctional epidermolysis bullosa 
MC: mast cells. 
MBP: major basic protein  
MDSC: Myeloid-derived suppressor cells. 
M-MDSC: Monocytic-Myeloid-derived suppressor cells  
xv 
 
MPO: Myeloperoxidase  
PMN-MDSC: Polymorphonuclear-Myeloid-derived suppressor cells. 
qPCR: quantitative polymerase chain reaction 
SCC: squamous cell carcinoma 
TNFα: tumor necrosis factor α 
TSLP: thymic stromal lymphopoietin  
WT: wild type 
1 
 
CHAPTER 1   BACKGROUND 
1.1 BP180 and the hemidesmosome 
BP180, also known as collagen XVII, is a structural protein which plays a critical 
role in maintaining the linkage between the intracellular and the extracellular structural 
elements involved in epidermal adhesion. The gene encoding BP180 (Col17A) was first 
isolated from human keratinocytes in 1990 and identified as a hemidesmosomal protein 
by the group led by Dr. Luis A. Diaz (Diaz et al. 1990). The gene encoding BP180 is 
located in the long arm of chromosome 10, locus 10q24.3 (Diaz et al. 1990). BP180 
plays a key role in maintaining skin integrity through the hemidesmosome (Nahidiazar et 
al. 2015). In order to anchor epidermal keratinocytes into the underlying basement 
membrane, BP180 interacts with other proteins to form the hemidesmosome, which 
include BP230, plectin, keratins 5/14, integrin α6β4 and type VII collagen (Nahidiazar et 
al. 2015).  
 
BP180 is a type II transmembrane glycoprotein: the extracellular carboxyl-
terminal half of BP180 consists of 15 collagen domains and 16 non-collagen domains.  
The extracellular domain consists of a C-terminal 1007 amino acid sequence that is 
predicted to extend into the basal lamina region adjacent to the basal keratinocytes. The 
numbering of the collagen and non-collagen domain starts at the C-terminus (Figure 
1.1) (Borradori et al. 1998).
2 
 
 
 
Figure 1.1 The structure of BP180 protein. BP180 (Collagen XVII) is a 
transmembrane glycoprotein expressed by skin basal keratinocytes. It has a mostly 
non-collagen intracellular domain, a transmembrane domain and an extracellular 
domain with 15 collagen domains (black bars). The non-collagen domain NC16A 
contains the major epitope for autoantibodies in the patients of bullous pemphigoid 
(BP). In order to generate a human BP animal model, we generated humanized NC16A 
mice by replacing mouse NC14A with the human NC16A domain.    
 
The main established function of BP180 is cell-extracellular matrix (ECM) adhesion 
in skin. It anchors epidermal basal keratinocytes to the basement membrane, through 
its collagenous region, which binds to laminin 332 (previously known as laminin 5) (Van 
Den Bergh et al. 2011)(Bergh et al. 2011). Also, BP180 plays a key role in the hair 
follicle stem cells to maintain the aging process and melanocyte niche (Tanimura et al. 
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2011)(Matsumura et al. 2016). In addition, BP180 also plays a role in keratinocyte 
migration through β4 integrin signaling (Löffek et al. 2014). Therefore, BP180 is not only 
a cell-ECM adhesion molecule, its diverse physiological functions need broader 
investigation.    
 
1.2 Skin inflammatory diseases and BP180 
BP180 dysfunction leads to skin blister diseases with inflammatory features, 
which include bullous pemphigoid (BP) and junctional epidermolysis bullosa (JEB). BP 
is caused by autoreactive antibodies targeting BP180 in patients (Nousari and Anhalt 
1999)(Leighty et al. 2007). JEB is caused by genetic mutations of BP180 gene (Kiritsi 
et al. 2011)(Fine 2010a)(Jonkman et al. 1982).  
 
1.2.1 Autoimmune bullous pemphigoid 
BP is an autoimmune skin blistering disease which occurs most commonly in the 
elderly population (Hammers and Stanley 2016). The skin lesions on BP patients 
include urticarial plaques, tense blisters and sometimes bullous eruptions (Nousari and 
Anhalt 1999). Histological examination in BP shows subepidermal blistering, with many 
infiltrating neutrophils and eosinophils along the basement membrane and blister cavity 
(Nousari and Anhalt 1999). Direct immunofluorescence of perilesional skin shows IgG 
and C3 deposition along the basement membrane (Leighty et al. 2007)(Hammers and 
Stanley 2016). Indirect immunofluorescence of serum IgG shows circulating IgG 
autoantibodies binding to the basement membrane of human skin. Patients also suffer 
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from severe itchy sensations (Nousari and Anhalt 1999)(Leighty et al. 2007)(Hammers 
and Stanley 2016).  
 
Since the 1970s, scientists started to develop an animal model for human BP. 
However, due to the fact that amino acid sequence of the autoantigen, NC16A, is poorly 
conserved in murine BP180 NC14A, passive transfer of BP patient serum failed to 
demonstrate BP in an animal setting (Liu et al. 1993). To tackle this issue, our lab 
generated a humanized mouse model replacing the mouse NC14A domain with human 
NC16A (termed hNC16A mice, or WT mice). Therefore, we can passively transfer 
patient antiserum into hNC16A mice to replicate human BP disease in vivo (Liu et al. 
2008)(Leighty et al. 2007). 
1.2.2 Junctional epidermolysis bullosa (JEB) 
Mutations in COL17A1, the gene encoding BP180, lead to junctional 
epidermolysis bullosa (Junctional EB, JEB) (Jonkman et al. 1995). EB refers to a group 
of heterogeneous heritable disorders characterized by skin fragility, the formation of 
blisters at sites of minor friction or trauma, and impaired wound healing (Fine 
2010b)(Fine 2010a). EB diseases are categorized into three major groups based on 
whether blistering occurred within the epidermis (EB simplex), within (junctional EB) or 
just beneath (dystrophic EB) the entire skin basement membrane zone (Fine 2010b). 
(Figure 1.2) 
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Mutations in 14 different genes, which are related to the cutaneous basement 
membrane zone, lead to EP diseases (Uitto et al. 2016). In addition, mutations on the 
genes encoding laminin 322, α6β4 integrin and BP180, can lead to JEB (Fine 2010a). 
Junctional EB (JEB) is characterized into two major subtypes: Herlitz JEB and non-
Herlitz JEB (Sawamura et al. 2010). Herlitz JEB is the more severe form of the 
condition. From birth or early infancy, affected individuals have blistering over large 
regions of the body. Because the signs and symptoms of Herlitz JEB are so severe, 
infants with this condition usually do not survive beyond the first year of life. The milder 
form of JEB is called non-Herlitz JEB (JEB-nH). Its blistering may be limited to the 
hands, feet, knees, and elbows, and it often improves after the newborn period. Most 
affected individuals do not have extensive scarring or granulation tissue formation, so 
breathing difficulties and other severe complications are rare. JEB-nH is typically 
associated with a normal lifespan (Sawamura et al. 2010)(Lin and Carter 1993)(Uitto et 
al. 2016). 
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Figure 1.2 Epidermolysis bullosa (EB). Based on the level of tissue separation and 
the genes mutated which are the cause of the disease, there are three types of EB: EB 
simplex; junctional EB and dystrophic EB. (Adapted from Daisuke Sawamura, J. 
Dermatol. 2010;37(3):214–219.) 
 
Herlitz JEB results from severe mutations within any of the three genes which 
encode for the three chained adhesion protein laminin-332 (previously called laminin-5).  
The majority of patients with JEB-nH have less severe mutations within the same 
targeted genes, although a minority have mutations instead within the gene 
COL17A1(Fine 2010a). Mutations in the COL17A1 gene prevent the normal function of 
BP180. As a result, the skin is less resistant to friction and minor trauma and forms 
blisters easily. There are  around 60 reported cases of BP180 mutations (Kiritsi et al. 
2011) and most COL17A1 gene mutations cause a form of non-Herlitz JEB, called 
generalized atrophic benign epidermolysis bullosa (GABEB) (Jonkman et al. 1982). The 
clinical features of GABEB are continuous blistering since birth, cigarette paper-like 
atrophic depigmented skin at the sites of recurrent blistering, normal growth, lack of 
anemia, moderate improvement during aging, dystrophic nails and minor/partial hair 
loss. Although there is no effective treatment  for any of the EB diseases yet, 
developments in gene therapy, protein replacement therapy and cell-based therapy 
have been reported (Uitto 2008)(Fine 2010b)(Fine 2010c)(Uitto et al. 2016).   
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1.2.3 The possible correlation between BP180 dysfunction and skin inflammation. 
Previous reports have shown that itch is one of the most bothersome symptoms 
in BP, EB and JEB (Nousari and Anhalt 1999)(Hammers and Stanley 2016)(Snauwaert 
et al. 2014)(Mabuchi et al. 2007). Atopic dermatitis (AD) is one of the most common 
inflammatory skin disease in children and its symptoms include losing skin barrier 
function, increased serum IgE, infiltrating inflammatory immune cells, epidermal 
hyperplasia and itch (Bieber 2008). Even though JEB is a very rare disease and there 
are very limited cases of JEB with BP180 mutation (Kiritsi et al. 2011), we found two 
reported cases indicating that JEB patients with COL17A1 mutations show significantly 
increased itch and skin inflammation, accompanied with a significant increase in 
eosinophil skin infiltration (Mabuchi et al. 2007)(Cifuentes et al. 2013). In addition, AD 
can co-occur with EB (Lapinski et al. 1998)(Sibaud et al. 2002)(Snauwaert et al. 2014). 
A reported clinical case found that children can have a combination of EB and AD 
(Snauwaert et al. 2014). There are also two cases reported of patients diagnosed as EB 
with concomitant AD that had an exacerbated blistering condition (35, 36). Based on the 
clinical findings above, we hypothesized that BP180 dysfunction may promote skin 
inflammation/dermatitis even without autoimmunity (such as BP). In addition, this 
hypothesis later developed into another hypothesis that BP180 dysfunction may trigger 
a skin inflammation which promotes melanoma progression (discussed in Chapter 3). 
 
1.3  Inflammation, myeloid-derived suppressor cells (MDSCs), mast cells and 
cancer/melanoma progression 
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1.3.1 Inflammation and cancer 
Cancers are known to be caused by genetic mutations; however, more recent 
findings have shown that the immune system, especially inflammation, also plays a 
crucial role in cancer development. The first documented proposition of an association 
between inflammation and cancer has been attributed to the German pathologist Rudolf 
Virchow in the mid-19th century (Grivennikov et al. 2010).  In  recent  decades, the 
scientific field has gradually recognized that tumor-associated inflammation is  a key 
hallmark of cancer (Hanahan et al. 2011)(Grivennikov et al. 2010)(Colotta et al. 2009). 
The reason is that the vast majority of cancers (90%) are linked to somatic mutations 
and environmental factors, and most of the environmental causes of cancer and risk 
factors are associated with some form of chronic inflammation (Grivennikov et al. 2010).  
 
There are four major types of inflammation which promote tumorigenesis and 
cancer progression (Figure 1.3): 1) Inflammation caused by environmental and dietary 
exposure e.g., smoking. 2) Therapy-induced inflammation during cancer treatments. 3) 
Tumor-associated inflammation, e.g., inflammatory cytokines secreted by tumor cells. 4) 
Chronic inflammation caused by infection or other causes. My research project is 
focusing on the role of chronic inflammation triggered by BP180 dysfunction in 
promoting melanoma progression (in Chapter 3).   
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  Figure 1.3 Types of Inflammation in cancer progression. The inflammatory 
responses which promote tumor progression and tumorigenesis are marked in purple, 
for example: promoting angiogenesis, immunosuppression and metastasis. However, in 
some cases, therapy-induced inflammation can also enhance antigen presentation, 
leading to immune-mediated tumor eradication. (Adapted from Grivennikov et al., Cell. 
2010;140:883–899.) 
 
Inflammation promotes cancer progression mainly through two mechanisms: 1) 
by increasing the genetic mutation rate or promoting genomic instability, which 
eventually leads to tumorigenesis; or 2) by creating a microenvironment which promotes 
the progression of existing tumor cells. In other words, inflammation may help existing 
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tumor cells to proliferate, survive and metastasize independently from acquiring new 
genetic mutations. The inflammatory microenvironment can stimulate angiogenesis, 
cause localized immunosuppression, and promote the formation of a hospitable 
microenvironment in which malignant cells can survive, expand and eventually 
metastasize (Grivennikov et al. 2010). It is this second mechanism that I will address in 
Chapter 2 of my thesis. 
 
The pro-inflammatory tumor microenvironment is a very complicated system 
composed of various players, which includes tumor cells, untransformed host cells and 
cytokines/chemokines. Untransformed host cells, which include immune cells and 
stroma cells, play dual roles in both supporting and inhibiting tumor progression, 
especially immune cells. Beginning in the 1970s, immune cells were considered to play 
a significant role in anti-tumor immunological surveillance (Burnet 1970). Therefore, for 
the transformed cells to establish tumor growth, they have to use various methods to 
bypass immunosurveillance, which includes immunoediting (constant changing of tumor 
surface markers), MHC downregulation and induction of immunogenic tolerance 
(Shalapour and Karin 2015). Tumors have been considered “the wound that never 
heals”, and tumor cells promote a chronic inflammatory microenvironment (Trinchieri 
2012)(Grivennikov et al. 2010)(Coussens and Werb 2002).  Chronic inflammation, 
especially triggered by tumor cells, can shape both local and systemic immunity to 
promote formation of an immunosuppressive tumor microenvironment through 
cytokines/chemokines and the influx of inflammatory immune cells, including MDSCs 
and mast cells (Shalapour and Karin 2015). 
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1.3.2 Myeloid-derived suppressor cells (MDSCs) 
Myeloid-derived suppressor cells (MDSCs) are defined as a group of 
heterogeneous immature myeloid cells with immunosuppressive functions, which play a 
key role in linking chronic inflammation and tumor progression in vivo (Ostrand-
Rosenberg and Sinha 2009a)(Condamine et al. 2015). MDSCs inhibit anti-tumor 
immune surveillance and promote tumor progression. MDSCs express the surface 
markers CD11b+Gr1+ in mice (Gr1 comprised of two surface markers, Ly6G and Ly6C), 
and are comprised of two groups of cells, CD11b+Ly6G+Ly6C- polymorphonuclear-
MDSCs (PMN-MDSCs) and CD11b+Ly6G-Ly6C+ monocytic-MDSCs (M-MDSCs)(Youn 
et al. 2008b)(Bronte et al. 2016). PMN-MDSCs share the same surface markers and 
morphology with neutrophils (PMNs), while M-MDSCs share similar surface markers 
with monocytes. However, unlike the neutrophils and monocytes in healthy individuals, 
MDSCs exhibit the ability to suppress the immune response against tumor (Ostrand-
Rosenberg and Sinha 2009a)(Condamine et al. 2015)(Youn et al. 2008a)(Bronte et al. 
2016). 
 
MDSCs result from the expansion of myeloid precursor cells in bone marrow in 
response to chronic inflammation, infection, trauma and cancer (Talmadge and 
Gabrilovich 2013)(Ostrand-Rosenberg and Sinha 2009a). So far, the exact combination 
and sequence of tumor-derived and micro environmental factors that regulate MDSC 
mobilization, proliferation, abnormal differentiation and activation remain largely 
unknown compared to other types of immune cells (Talmadge and Gabrilovich 2013). 
Normal myeloid cells and MDSCs are all derived from immature myeloid cells (IMCs). In 
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normal physiological conditions, IMCs are part of the normal process of myelopoiesis, 
which is controlled by a complex network of cytokines produced by bone marrow, which 
includes GM-CSF, M-CSF, SCF, G-CSF, IL3, FLT3 and other soluble factors. IMCs 
migrate to different peripheral organs and differentiate into macrophages, dendritic cells 
and neutrophils under normal conditions. However, the factors described above are also 
produced during acute/chronic inflammation and in tumor microenvironments at these 
sites. As a result, IMCs gradually developed into MDSCs, accumulate in circulation, 
spleen and the site of inflammation/tumor (Gabrilovich et al. 2012)(Kumar et al. 
2016)(Gabrilovich and Nagaraj 2009). PMN-MDSCs may eventually differentiate into 
tumor associated neutrophils (TANs) and M-MDSCs may eventually differentiate into 
tumor associated macrophages (TAMs), which may still retain immunosuppressive 
functions and promote tumor progression (Bronte et al. 2016).  
 
MDSCs eventually traffic from bone marrow toward the tumor with a gradient of 
different chemokines dependent on different types of tumor and microenvironment 
which is still not fully understood (Kumar et al. 2016). So far, it is known that the 
chemokines which recruit MDSCs to the site of inflammation and tumor include CCL2, 
CXCL1/2 (IL8 in human), CCL5, CXCL5, CXCL6, CCL15 and CXCL12 (Kumar et al. 
2016). The migration of MDSCs may depend on the chemokine receptors CXCR2, 
CXCR4 and CCR2 (Kumar et al. 2016). The number of circulating MDSCs is correlated 
with poor tumor prognosis in both humans and mice (Gabrilovich and Nagaraj 2009). 
Depletion of MDSCs by intraperitoneal injection of anti-Gr1 antibody has been shown to 
reduced MDSCs in mouse circulation and tumor volume (Ko et al. 2009)(Gabrilovich et 
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al. 2012)(Ostrand-Rosenberg and Sinha 2009b), including B16 melanoma tumor 
volume (Jablonska et al. 2010).  
 
MDSCs inhibit immune responses through the expression of immunosuppressive 
molecules. To inhibit the antigen-specific cytotoxic T cell response against tumor cells, 
MDSCs use two different immunosuppressive enzymes: inducible nitric oxide synthase 
(iNOs) or arginase-1. M-MDSCs, which have monocyte-like morphology, preferentially 
express iNOs, while PMN-MDSCs, which have neutrophil like morphology, express a 
high levels of arginase-1 (Movahedi et al. 2008). Both types of MDSCs inhibit the T cell-
mediated anti-tumor response. MDSCs expressing arginase-1 reduce the availability of 
L-arginine, and as a result, T cells lose the expression of CD3ζ, which impairs their anti-
tumor function. The production of NO through iNOs can also impair T cell function 
through multiple pathways that are independent of arginase-1(Talmadge and 
Gabrilovich 2013)(Gabrilovich and Nagaraj 2009)(Nagaraj et al. 2014). Besides the 
production of arginase-1 and NO, MDSCs can also inhibit anti-tumor immunity through 
the production of reactive oxygen species (ROS), and immunoregulatory cytokines and 
chemokines, such as IL10 and TGFβ. To date, reports suggest that M-MDSCs are more 
potent than PMN-MDSCs in promoting tumor progression in vivo (Youn and Gabrilovich 
2010). 
 
The expansion of MDSCs is mediated by increased proliferation, resistance to 
apoptosis and inhibition of differentiation into dendritic cells (DCs) and macrophages. In 
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addition to evasion of immunosurveillance, MDSCs may also promote tumor 
progression through increased angiogenesis (Murdoch et al. 2008). MDSCs inhibit T 
cell-mediated anti-tumor immunity while T cell activation eliminates MDSCs through 
Fas-mediated apoptosis [35]. In summary, I hypothesized that BP180 dysfunction 
triggers a skin inflammatory microenvironment, which leads to the accumulation of 
MDSC in skin local microenvironment and eventually leads to increased tumor 
progression.  
1.3.3 Mast cells 
Mast cells are granulated tissue-resident cells and function as regulators of 
immunity, especially inflammation (St John and Abraham 2013). Mast cells accumulate 
in various types of skin cancer, including melanoma (Ch’ng et al. 2006). The infiltration 
of mast cells positively correlates with the severity of melanoma (Duncan et al. 1998). 
Upon activation, mast cells release inflammatory mediators from their cytoplasmic 
granules. The granules of mast cells are packed with immunoregulatory and 
proinflammatory mediators, including heparin, protease, TNFα, and histamine. Mast cell 
promoted B16 melanoma progression, and B16 melanoma progression is significantly 
reduced in mast cell-deficient mice (Starkey et al. 1988)(Oldford et al. 2014). However, 
the exact role that mast cells play in tumor progression is relatively less known and 
more research is needed to develop anti-melanoma therapy by targeting mast cells.  
 
There is a positive correlation between mast cell density in the dermis and the 
susceptibility to ultraviolet B induced immunosuppression, which may promote 
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cutaneous carcinogenesis (Hart et al. 2001)(Townley et al. 2002). However, the 
mechanism by which mast cells may promote immunosuppression is still unclear. 
Recently, it was reported that mast cells are required for B16 melanoma metastasis 
promoted by MDSCs (Saleem et al. 2012). Also, mast cells were reported to promote 
hepatocarcinoma progression through increasing the trafficking of MDSCs (Yang et al. 
2010). These findings suggest that mast cells play a role in melanoma progression 
through their interaction with MDSCs (Chen et al. 2015). In my research, we link mast 
cells and MDSC with basal keratinocytes through the skin inflammation triggered by 
BP180 dysfunction.  
 
1.4 Known correlation between altered expression of BP180 and skin cancers 
Since the 1980s, multiple reports have shown that altered BP180 expression is 
positively associated with various types of skin cancers, including squamous cell 
carcinoma (SCC) (Parikka et al. 2003)(Parikka et al. 2006)(Stelkovics et al. 
2008)(Karppinen et al. 2016), basal cell carcinoma (BCC) (Parikka 2001), and 
melanoma (Krenacs et al. 2012). BP180 is also reported to be associated with the 
invasiveness of SCC (Herold-Mende et al. 2001)(Moilanen et al. 2015) and colorectal 
cancer (Moilanen et al. 2015). Untransformed melanocytes do not express BP180; 
when transformed, however, melanoma cells acquire the expression of BP180 as it 
increases its invasiveness (Krenacs et al. 2012). However, it is still unclear whether that 
the BP180 expressed by skin basal keratinocytes plays a positive or negative in 
melanoma progression and we investigated the question in the Chapter 3 of this 
dissertation  
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Recent findings indicate that skin keratinocytes can affect the metastasis of 
nearby melanoma cells (Golan et al. 2015). When melanoma cells are at the early 
stage, they are surrounded by basal keratinocytes and invasiveness is suppressed 
(Golan et al. 2015). However, as the melanoma cells progress and directly contact the 
differentiated epidermal cells, Notch signaling triggered invasion is activated (Golan et 
al. 2015). This finding shows that keratinocytes may play an important role in the 
progression of melanoma cells. To our knowledge, there is no report showing BP180 in 
skin basal keratinocytes may play a role in affecting melanoma progression. However, It 
is reported that BP180 null human keratinocytes secrete significantly increased CXCL1 
in response to LPS or TNFα stimulation compared to BP180 sufficient human 
keratinocytes in vitro (Van den Bergh et al. 2012). CXCL1 is one of the major 
chemoattractants for MDSCs, especially for PMN-MDSCs (Sawanobori et al. 2008). 
Therefore, this finding indicates that BP180 may also play a role in tumor progression 
through modulating chemokine secretion from keratinocytes.  
 
1.5 Mouse model for BP180 physiological functions 
Currently, the only established function of BP180 is as a cell/ECM adhesion 
molecule, which is supported by the disease JEB, caused by mutations in the BP180 
gene COL17A1  (Jonkman et al. 1982). Initially, BP180 null (Col17a1-/-) mice were 
developed as a tool by two groups to investigate the function of BP180 in vivo (Nishie et 
al. 2007)(Hurskainen et al. 2012). One line, termed Col17m- were developed by Dr. Emi 
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Nishimura et al in Japan (Nishie et al. 2007). With the mouse model, Dr. Nishimura’s 
group found BP180 plays a crucial role in the aging of hair follicle stem cells (HFSC), 
and maintains a functional niche for melanocyte stem cells through the aging process of 
HFSC (Tanimura et al. 2011)(Matsumura et al. 2016). However, considering that more 
than 80% of all Col17m- mice died before two weeks after birth, this imposed a 
significant limitation on using BP180 null mice to investigate the function of BP180 in the 
context of disease progression. Dr. Kaisa Tasanen’s group in Finland also developed a 
BP180 null mouse called Col17a1-/- (Hurskainen et al. 2012). The Col17a1-/- was 
developed with a similar strategy compared to Dr. Nishimura’s group, and also showed 
a similar mortality rate; 90% of them died within two week of birth. Therefore, the high 
mortality rate of BP180 null mice severely restricts its application in investigating BP180 
function in vivo. 
 
To tackle this issue, there are at least two groups who developed a truncated 
BP180 mouse model, (including our group). One group is the Dr. Kaisa Tasanen’s 
group in Finland. Dr. Tasanen’s group generated a mouse model (termed ∆NC14A) 
expressing truncated BP180 protein lacking NC14A (the mouse homologue of human 
NC16A)(Hurskainen et al. 2014). The ∆NC14A mice can live up to 13 months after birth. 
The ∆NC14A mice exhibit skin inflammation with a predominantly eosinophil infiltration 
into its skin starting two months after birth. In addition, around 43% of all ∆NC14A mice 
developed scratching behavior starting 10~16 weeks after birth, and more than 80% of 
all ∆NC14A mice developed scratching behavior at 1 year after birth. This finding 
indicates that BP180 dysfunction may promote skin inflammation with itch.       
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To develop the BP passive transfer mouse model, our lab generated a humanized 
mouse with the mouse NC14A domain being replaced with the human NC16A domain 
(termed hNC16A or WT mice). Our lab purposely flanked the NC16A-encoding 
sequence with loxP sites (Liu et al. 2008). As we crossed the humanized NC16A mice 
with mice carrying different promoter-driven Cre genes, we generated systemic or 
conditional NC16A deficient mice (termed ∆NC16A). With conditional ∆NC16A mice, we 
can investigate the role of BP180 in local skin and basal keratinocytes in vivo. 
  
1.6 Working hypothesis for my dissertation 
In my thesis work, we hypothesized that BP180 may play a diverse role in skin 
basal keratinocytes, not only as a cell/ECM adhesion molecule, but also modulating the 
skin inflammatory microenvironment. BP180 dysfunction may trigger proinflammatory 
cytokine secretion from basal keratinocytes, which promotes skin inflammation.   
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CHAPTER 2 
The dysfunction of BP180/collagen XVII in keratinocytes leads to mast cell-
dependent skin infiltration of myeloid derived suppressor cells and accelerated 
melanoma progression1 
 
2.1 OVERVIEW AND SIGNIFICANCE 
Overview 
BP180, also termed collagen XVII, is a hemidesmosomal transmembrane 
glycoprotein expressed in basal keratinocytes, and functions as a cell-matrix adhesion 
molecule in the dermal-epidermal junction of the skin. While altered expression of BP180 
has been shown in melanoma, whether BP180 is directly involved in melanoma 
progression remains unknown. We have previously generated a mouse strain with BP180 
dysfunction (termed ∆NC16A), which develops spontaneous skin inflammation 
accompanied by an influx of mast cells (MCs) and myeloid derived suppressor cells 
                                                          
 
1 My contributions: Bin-Jin Hwang designed the concept of this project, developed the 
experimental methodology, performed the experiments, acquired most data, analyzed 
the data and wrote the manuscript. This chapter has been prepared to the following 
manuscript and is under reviewing in the Journal of “Oncogene”: 
Hwang BJ, Zhang Y, Brozowski J, Liu Z, Burrette SW, Lough K, Li N, Williams SE, Su M,  
Thomas N, Diaz L,  and Liu Z. 
BP180/collagen XVII dysfunction in keratinocytes leads to accelerated melanoma progression. 
 
(MDSCs). Here, we utilize the B16 mouse melanoma model to demonstrate that BP180 
dysfunction in either skin or basal keratinocytes promotes skin inflammation and tumor 
progression. MC-deficient ∆NC16A mice had drastically reduced MDSCs in the skin and 
show reduced melanoma progression, restored by local reconstitution of MCs. MDSC 
depletion also reduced tumor progression in MC-sufficient ∆NC16A mice, demonstrating 
a critical role for the MC-mediated MDSC inflammatory response in melanoma 
progression.  
SIGNIFICANCE: 
This study provides the first direct evidence that BP180, a cell-cell matrix adhesion 
molecule, possesses anti-tumor function through modulating infiltration of MCs and 
MDSCs. Basal keratinocytes actively participate in skin proinflammatory 
microenvironment changes caused by a BP180 dysfunction. ∆NC16A mice could be a 
new animal model in which to study the melanoma microenvironment.  
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2.2 INTRODUCTION  
BP180, also known as collagen XVII, is a transmembrane glycoprotein of the 
hemidesmosome (Hammers and Stanley 2016). The intracellular region of BP180 is 
linked to the intermediate filament network, and its extracellular portion is anchored into 
the basement membrane zone (BMZ) through interacting with extracellular matrix 
proteins (Koster et al. 2003)(Hopkinson and Jones 2000)(Margadant et al. 2008). In the 
skin, BP180 serves as a critical cell-cell matrix adhesion molecule to maintain the 
integrity in dermal-epidermal junction. Loss of BP180 function either by mutations in the 
COL17A1 gene in the genetic disease termed junctional epidermolysis bullosa (JEB) or 
by autoantibodies against BP180 in the skin autoimmune disease bullous pemphigoid 
(BP) leads to subepidermal blistering in human and mice (Leighty et al. 2007)(McGrath 
et al. 1995). BP autoantibodies mainly target the extracellular non-collagenous 16A 
(NC16A) domain of BP180 (Van den Bergh et al. 2012)(Giudice et al. 1992). Antibodies 
against the human NC16A and the mouse corresponding NC14A of BP180 are 
pathogenic in antibody passive transfer models of BP (Nishie et al. 2007)(Liu et al. 
2008).  
  
Since the 1980s, multiple reports have shown that altered BP180 expression is 
associated with various types of skin cancers, including squamous cell carcinoma 
(SCC) (Parikka et al. 2003)(Parikka et al. 2006)(Stelkovics et al. 2008), basal cell 
carcinoma (BCC) (Parikka 2001), and melanoma (Krenacs et al. 2012). Untransformed 
melanocytes do not express BP180; when transformed, melanoma cells acquire the 
expression of BP180 (Krenacs et al. 2012). Epidermal keratinocytes can modulate the 
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metastasis of nearby melanoma cells (Golan et al. 2015); however, whether BP180 in 
basal keratinocytes is involved in skin cancer progression remains to be determined.  
 
It is well established that inflammation is crucial for cancer development 
(Hanahan et al. 2011). Mast cells (MCs) are the key regulator of tissue inflammation 
and various immune responses (Sayed et al. 2008). Tumor microenvironment has 
increased MC influx (Duncan et al. 1998)(Ch’ng et al. 2006)(Oldford et al. 2014). 
Recently, several reports showed that MCs play an important role in migration of MDSC 
to the tumor site (Yang et al. 2010) and melanoma progression promoted by MDSCs 
(Saleem et al. 2012).  
 
MDSCs play an important role in the progression of the various solid tumors, 
including melanoma (Talmadge and Gabrilovich 2013). MDSCs are characterized as 
CD11b+Gr1+ myeloid cells in mice (Kumar et al. 2016). They are a heterogeneous 
mixture of the immature myeloid cells, and are composed by two groups, Ly6G 
expressing polymorphonuclear like MDSC (PMN-MDSCs, previously also known as 
granulocytic-MDSCs) and monocytic like MDSCs (M-MDSCs) (Youn et al. 2008). 
MDSCs in the microenvironment promote tumor progression by suppressing immune 
surveillance, enhancing angiogenesis and promoting metastasis (Murdoch et al. 
2008)(Condamine et al. 2015).  
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To identify new biological functions of BP180, we generated a novel mouse strain 
carrying a deletion of the NC16A domain of BP180 (termed ΔNC16A mice). ΔNC16A 
mice developed spontaneous skin inflammation, and showed accelerated tumor 
progression when tested in the B16 mouse melanoma model. Our findings provide the 
first direct evidence that BP180 plays a role in modulating tumor microenvironment and 
melanoma progression. 
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2.3 RESULTS 
ΔNC16A Mice Develop Skin Inflammation With An Influx Of Mast Cells And 
MDSCs 
 
We previously generated a humanized NC16A mice (termed WT mice) by 
replacing the mouse NC14A domain with the human NC16A counterpart to study the 
disease mechanisms of BP (Liu et al. 2008). The NC16A domain is encoded by exons 
18 and 19 of BP180 gene, which were flanked by lox-P sites (Fig. 2.1A). When crossed 
with germline Cre mice, Cre recombination removes the loxP-flanked exons 18 and 19 
and maintains the remaining reading frame, resulting in mice expressing NC16A domain 
truncated BP180 (termed ΔNC16A). Genotyping of mouse tail DNA confirmed the lack 
of exons 18 and 19 in ΔNC16A mice (Fig. 2.1B). Lack of NC16A domain in ΔNC16A 
mice was confirmed by immunoblotting. Anti-NC16A antibody recognized full-length 
BP180 in the skin protein extract of WT mice and not ΔNC16A mice, while anti-NC1-3 
antibody interacted with both full-length BP180 in WT mice and NC16A truncated 
BP180 in ΔNC16A mice (Fig. 2.1C). Similarly, anti-NC16A antibody stained the skin of 
WT mice and not ΔNC16A mice, while anti-NC1-3 antibody stained the skin of both WT 
and ΔNC16A mice (Fig. 2.1D). 
 
ΔNC16A mice can live up to 12 months. Similar to previously described mice 
lacking NC14A domain (Hurskainen et al. 2014), ΔNC16A mice showed no clinical skin 
phenotypes after birth but began to develop minor skin lesions at the age of 8-12 weeks 
after birth (Fig. 2.1F, panel b). Histological examination revealed the low degree of 
dermal-epidermal separation in the skin of newborn and adult ΔNC16A mice starting at 
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the age of 8 weeks (Fig. 2.1F, panel d). In adult ΔNC16A mice, skin lesions were also 
accompanied by an infiltrate of immune cells (Fig. 2.1F, panel d), including neutrophils 
(Fig. 2.1E, panel f), T cells (Fig. 2.1E, panel j), and eosinophils (Fig. 2.1E, panel l) 
identified by immune staining, and significantly increased mast cells as identified by 
toluidine blue histochemical staining (Fig. 2.1F, panel l and Fig. 2.1E).  
 
BP180 was originally identified and extensively studied in epidermal 
keratinocytes of the skin (1; 4); but, it is also expressed in many other tissues/organs 
(23). To determine whether the skin inflammation seen in ∆NC16A was caused by 
deletion of NC16A in the skin or in non-skin tissues/organs, we generated tamoxifen 
inducible Cre-NC16A mice (termed TamCre-NC16A mice) by crossing NC16A mice with 
tamoxifen inducible Cre mice. When treated with tamoxifen topically, TamCre-NC16A 
mice became skin-specific ΔNC16A (termed SkinΔNC16A mice). Efficient deletion of 
NC16A deletion in skinΔNC16A mice was confirmed by PCR, RT-PCR, immunoblotting 
and immunofluorescence (Fig. S2.1). Like ΔNC16A mice with the whole body deletion 
of the NC16A domain, skin-specific ΔNC16A developed skin inflammation with 
increased skin infiltration of neutrophils, MCs, T cells and eosinophils, starting day 14 
post tamoxifen treatment (Fig. S2.2). WT mice treated with the same dose of tamoxifen 
did not develop skin inflammation and did not exhibit increased immune cell infiltration 
compared to the untreated WT mice, which rules out the inflammatory phenotype as the 
consequence of tamoxifen treatment instead of BP180 dysfunction (Fig. S2.2). The 
result from the Myeloperoxidase (MPO) assay, which serves as an indirect indicator of 
the quantity of neutrophil infiltration, further confirmed that skin-specific NC16A deletion 
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is sufficient to promote the influx of inflammatory neutrophils (Fig. S2.3). Results from 
cytokine array analysis also showed that there is a significant increase in the skin level 
of multiple proinflammatory cytokines of skinΔNC16A (Fig. S2.4). 
 
To determine whether ΔNC16A directly promotes skin inflammation through 
basal keratinocytes, we crossed NC16A mice with K14Cre mice to generate basal 
keratinocyte-specific ΔNC16A (termed K14Cre/ΔNC16A) mice (Fig. S2.5). Like 
ΔNC16A and skinΔNC16A mice, K14Cre/ΔNC16A also showed skin inflammation with 
significantly increased influx of MCs, neutrophils, T cells and eosinophils.  
 
Mice Lacking NC16A Exhibit Accelerated B16 Melanoma Progression 
Inflammation is one of hallmarks of cancer (Hanahan et al. 2011). Altered BP180 
expression was reported to be associated with the increased invasiveness of melanoma 
cells (Krenacs et al. 2012). We, therefore, hypothesized that BP180 in basal 
keratinocytes plays a role in melanoma progression through affecting the skin 
microenvironment. To test this hypothesis, WT and ΔNC16A mice were injected with 
B16 melanoma cells (1x105 cells, s.c) into the flank, and monitored for tumor 
progression for 3 weeks. Melanoma grew significantly faster in ΔNC16A mice compared 
to WT mice (Fig. 2.2A and 2B). The increased tumor growth in ΔNC16A mice was 
associated with a significantly reduced survival (Fig. 2.2C).  
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Mouse melanocytes are mainly distributed in hair follicles, while human 
melanocytes are located at the basal keratinocyte layer (Bleehen 1998). The only 
mouse sites that are comparable to human skin in terms of melanocyte distribution are 
on the ears and tail (Silvers 1979)(Bleehen 1998). Injection of melanoma cells into the 
ear has been considered a more clinically relevant model for human melanoma 
progression and metastasis (Rozenberg et al. 2010)(Bobek et al. 2010). Therefore, we 
injected B16 melanoma cells (1 x 106 cells) into the ears of WT and ΔNC16A mice and 
monitored the tumor growth locally on the ears and metastasis on the neck for 3 weeks 
(Fig. 2.2D). Similar to the flank injection model, tumor volumes were significantly 
increased in ΔNC16A mice compared to WT mice starting day 14 and day 21 after 
injection (Fig. 2.2E). 60% of ΔNC16A mice developed lymphatic metastases compare to 
none of the WT at 21 days post injection (Fig. 2.2F). These results demonstrated that 
NC16A deletion leads to drastically increased melanoma growth, metastasis and 
mortality, suggesting that BP180 plays a role in melanoma progression. 
 
Increased melanoma progression in ΔNC16A mice could be caused by local 
BP180 dysfunction and/or global deletion of NC16A leading to reduced systemic tumor 
suppression. To distinguish these, the same TamCre-NC16A mouse was topically 
treated at the left ear with tamoxifen and right ear with vehicle. Ten days later, both ears 
were injected with the same number of B16 melanoma cells (1x106 cells). Like ΔNC16A 
mice, tamoxifen-treated left ears showed significantly increased tumor growth and 
metastasis, whereas the control right ears showed no visible tumor growth 21 days after 
melanoma injection (Fig. 2.3A). Thus, we found local BP180 dysfunction affects B16 
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melanoma progression. To elucidate whether local skin BP180 dysfunction is sufficient 
enough to promote melanoma progression, we expanded our experiments to compare 
the tumor progression between WT mice treated with Tamoxifen (Control) and Tam-
CreNC16A (SkinΔNC16A) mice. SkinΔNC16A developed a significant increased tumor 
volume (Fig. 2.3B) and more lymphatic metastasis compare to the control mouse ears 
at 21 days post melanoma cell injection (77% of SkinΔNC16A vs. 20% of Control ears, 
Fig. 2.3C). More importantly, melanoma progression in skin-specific ΔNC16A mice is 
similar to whole body ΔNC16A mice (Fig. 2.3B and 3C). These results suggest that 
whole body deletion of NC16A domain does not alter systemic tumor immune-
surveillance, and the increased melanoma progression in ΔNC16A mice is caused by 
local deletion of NC16A in the skin. Therefore, BP180 local dysfunction is sufficient to 
promote B16 melanoma progression in vivo. 
BP180 is mainly expressed by basal keratinocytes in local skin (Leighty et al. 
2007). To test whether BP180 dysfunction in basal keratinocytes is sufficient to promote 
melanoma progression, K14Cre/ΔNC16A mice were injected at the ear with B16 
melanoma cells. Both tumor volumes (Fig. 2.3D and 3E) and metastasis (Fig. 2.3F) in 
K14Cre/ΔNC16A mice were comparable to whole body ΔNC16A mice, but significantly 
increased compared to WT mice starting on day 14 after injection. These results 
demonstrated that BP180 dysfunction in basal keratinocytes leads to increased 
melanoma progression through changing the skin microenvironment  
 
Mast Cells Play A Significant Role In The Melanoma Progression In ΔNC16A Mice. 
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MCs are critical in melanoma progression (Oldford et al. 2014)(Saleem et al. 
2012), and there is a significant increase in the skin influx of MCs in both ΔNC16A (Fig. 
2.1E, Fl) and skinΔNC16A mice (Fig. S2.2E ). To determine whether MCs play a role in 
increased melanoma progression in ∆NC16A mice, TamCre-NC16A mice were crossed 
with MC-deficient c-kiW-sh/W-sh (Wsh) mice (Grimbaldeston et al. 2005) to generate MC-
deficient TamCre-NC16A mice (termed TamCre-NC16AWsh). Upon topical tamoxifen 
treatment, TamCre-NC16AWsh mice became MC-deficient skin-specific ∆NC16A mice 
(skin∆NC16AWsh).  Skin∆NC16AWsh mice exhibited significantly reduced skin 
inflammation compared to MC-sufficient skin∆NC16A mice as evidenced by histological 
examination (Fig. 2.4A) and by measuring skin extract enzyme activity of MPO 
(neutrophil cell marker) (Fig. 2.4B). When tested in the B16 melanoma model, 
skin∆NC16AWsh mice showed significant reduction in tumor progression as compared 
to MC-sufficient skin∆NC16A mice (Fig. 2.4C and D).  
 
To rule out the possibility that reduced tumor progression in MC-deficient 
skin∆NC16A mice is due to c-kit mutation instead of MC deficiency, TamCre-
NC16AWsh and NC16AWsh mice (Cre negative, as control group) were reconstituted 
with 1x106 MCs at the ear for 6 weeks, then treated topically with tamoxifen. Ten days 
later, the mice were injected at the ear with 1x106 melanoma cells, and monitored for 
tumor progression for 3 weeks. The MC-reconstituted skin∆NC16AWsh mice exhibited 
a significantly increased tumor progression compared to the skin∆NC16AWsh mice 
without MC reconstitution (Fig. 2.4E and F). Thus, the reduced tumor progression on 
TamCre-NC16AWsh mice is the consequence of the absence of MCs.  
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Mast Cell-Dependent MDSC Influx Is Required for Increased Melanoma 
Progression in ΔNC16A Mice 
 
MCs play an important role in cutaneous cancers; however, their exact roles in 
skin cancers are relatively unclear (Ch’ng et al. 2006). One mechanism for MC-
promoting melanoma is that MCs help mobilize MDSCs to tumor site for MDSC pro-
tumor activity in melanoma (Yang et al. 2010)(Saleem et al. 2012). We, therefore, 
hypothesized that MCs promote melanoma progression through upregulating MDSC 
influx into the skin of ΔNC16A mice. 
 
Flow cytometry analysis was performed to test our hypothesis, and we found that 
there was a significantly increased MDSCs influx in the skin of ΔNC16A, skinΔNC16A 
and K14Cre/ΔNC16A mice (Fig. 2.5A), with PMN-MDSCs being predominant (Fig. 2.5B) 
and a smaller population of M-MDSCs (Fig. 2.5C). Taken together, these results 
demonstrate that BP180 dysfunction in basal keratinocytes or local skin is sufficient to 
promote the infiltration of MDSCs into the skin of ΔNC16A mice. PMN-MDSCs had 
been reported to express MPO and play a vital role in the development of solid tumors 
(Kumar et al. 2016). Also, skin infiltration of PMN-MDSCs in MC-deficient skin∆NC16A 
was significantly reduced as indirectly determined by measuring skin MPO activity (Fig. 
2.4B), showing an association between MCs and PMN-MDSCs infiltration. To better 
determine whether MDSC skin infiltration requires MCs in mice lacking NC16A, we 
quantified and compared skin levels of PMN-MDSCs and M-MDSCs between MC-
sufficient and MC-deficient skin∆NC16A mice by flow cytometry. MC-deficient 
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skin∆NC16A mice exhibited a significant reduction of both PMN-MDSCs and M-MDSCs 
compared to MC- sufficient skin∆NC16A mice (Fig. 2.6A-C). Furthermore, MC 
reconstitution restored the MDSC infiltration in MC-deficient skin∆NC16A mice (Fig. 
2.6A-C). These results demonstrated that MDSC skin infiltration is dependent on MCs. 
More significantly, skin∆NC16A mice treated with anti-Gr1 antibody to deplete Gr1 
positive MDSCs (Gr1+ cells include both Ly6G+ and 6C+ populations) showed 
significantly reduced Gr1 positive immune cells in the skin (Fig.S2.6), melanoma tumor 
volume (Fig. 2.6D) and the rate of developing metastasis (Fig. 2.6E). Taken together, 
these results demonstrated that MC-dependent MDSC infiltration is crucial for 
accelerated melanoma progression caused by BP180 dysfunction.  
 
In conclusion, BP180 dysfunction in basal keratinocytes promotes the 
accumulation of mast cells (MCs) in local skin; the increased MCs promote MDSC influx 
and eventually promote melanoma progression (Fig. 2.7). 
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2.4 DISCUSSION  
BP180 is well established as a key cell-matrix adhesion molecule in the skin 
(Leighty et al. 2007). In this study, we used the ∆NC16A mouse strain and found that 
mice with dysfunctional BP180 develop a spontaneous skin inflammation and exhibit 
accelerated melanoma progression when challenged with B16 mouse melanoma cells. 
Our findings provide the first direct evidence linking BP180 and melanoma progression. 
Our in vivo and in vitro data also identified critical cellular events involved in this newly 
developed model of melanoma: 1) Basal keratinocytes with deletion of BP180’s NC16A 
region recruit MCs into the skin; 2) Increased infiltrating MCs recruit MDSCs to create a 
proinflammatory microenvironment in local skin; and 3) Increased infiltrating MDSCs 
promote melanoma progression (Fig. 2.7). These findings show that MCs are a critical 
cellular link between dysfunction of BP180 in basal keratinocytes and MDSCs during 
melanoma progression in our model setting. However, how BP180 dysfunction leads to 
increased MC infiltration in the skin remains to be determined. Our future studies will 
aim to identify mediators critical for MC recruitment.    
 
JEB is a rare autosomal recessive disorder caused by defects in genes encoding 
hemidesmosomal proteins and hemidesmosome-associated proteins including α6β4 
integrin, BP230, BP180, laminin 332 and collagen VII (Fine 2010a)(Bubier et al. 2010). 
BP180 mutations lead to the partial or complete loss of BP180 function, which causes 
JEB, most commonly non-Herlitz JEB (Fine 2010b)(Kiritsi et al. 2011). The symptoms of 
non-Herlitz JEB caused by BP180 mutation includes itch and the infiltration of 
proinflammatory immune cells into skin (Mabuchi et al. 2007), which share phenotypical 
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similarity with our ∆NC16A mice and the reported NC14A deficient mice (Hurskainen et 
al. 2014). Not only sharing the symptoms of BP180 mutated patients, ∆NC16A mice 
also exhibit minor dermal-epidermal separations starting at around eight weeks after 
birth, which further indicate that lacking the NC16A domain of BP180 significantly 
jeopardizes the normal cell/ECM adhesive function of BP180. Our ∆NC16A mouse 
model is a dysfunctional BP180 animal model, which reflects some pathophysiological 
features of JEB, including skin inflammation and subepidermal blistering (Fine 
2010a)(Kiritsi et al. 2011)(Mabuchi et al. 2007).  There is a case report showing a 
patient with BP180 mutation developed JEB, which shared phenotypical similarity with 
∆NC16A mice which includes itch and inflammatory immune cell influx (Mabuchi et al. 
2007). This case report supports the clinical relevance of our ∆NC16A mouse model as 
the physiological consequence of BP180 dysfunction in patients (Mabuchi et al. 2007). 
 
From a study based on 43 European JEB patients with BP180 mutations, the 
patient group exhibited a wide spectrum of clinical variabilities, from mild to severe 
phenotypes of JEB symptoms (Kiritsi et al. 2011). In general, the milder forms of JEB 
are associated with missense or splice-site mutations and the presence of truncated 
BP180 protein in skin (Kiritsi et al. 2011). Because our ∆NC16A mice still express a 
truncated form of BP180 and do not show symptoms before eight weeks old, we 
consider our ∆NC16A mouse as a dysfunctional BP180 mouse model representing a 
relatively milder form of JEB. Our model shares similarity with reported JEB cases with 
skin inflammation (Mabuchi et al. 2007). 
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Due to the rarity of all EB disease combined, in which the prevalence of all EB 
disease is less than eight per one million population, and melanoma only accounting for 
less than 5% of all skin cancers, only limited case reports indicate an increased risk of 
melanoma associated with any types of EB diseases (Fine et al. 2009)(Mallipeddi 
2002). But, JEB is linked to significantly increased susceptibility to SCC (Fine 
2012)(Mallipeddi 2002). A research based on clinical data collected between 
1986~2002 in the US also found children with recessive dystrophic EB have increased 
susceptibility to melanoma (Fine et al. 2009). Nevertheless, our animal model findings 
do provide the reverse-genetic evidence, implicating that the melanoma in patients with 
BP180 deficiency, such as JEB, may progress more severely, compared to patients with 
functional BP180. Future clinical studies with more cases of JEB associated with 
melanoma may provide more definite evidence to support our conclusion.  
 
Skin cancers, including SCC (Parikka et al. 2003)(Parikka et al. 2006)(Stelkovics 
et al. 2008), BCC (Parikka 2001), and melanoma (Krenacs et al. 2012) are associated 
with altered BP180 expression, often having increased levels of the protein. BP180  
binding partners, including α6β4 integrin and laminin 332, also play a pro-cancer role in 
cancer cell adhesion and motility (Stewart and O’Connor 2015)(Van Den Bergh et al. 
2011). To our surprise, BP180 plays a negative role in melanoma progression in 
∆NC16A mouse model: dysfunction of BP180 in basal keratinocytes surrounding 
melanoma cells facilitates tumor growth and metastasis. Since exogenous BP180-
replete B16 melanoma tumor cells were injected into ∆NC16A mice, altered expression 
or deficiency of BP180 may play different roles in the initiation vs. growth phase of 
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development of melanoma and other skin cancers. Future studies would need to directly 
address this scenario.  
 
MCs are crucial in tissue inflammation and MDSC recruitment to the tumor 
location, helping MDSCs promote melanoma progression (Sayed et al. 2008)(Duncan et 
al. 1998)(Ch’ng et al. 2006)(Oldford et al. 2014)(Yang et al. 2010)(Saleem et al. 2012). 
Increased expression of key MC and MDSC tissue homing chemokines both at mRNA 
and protein levels and infiltrating MC and MDSC are present in the skin of ∆NC16A 
mice (Fig. S2.4 and Table 2.1). More importantly, MDSC recruitment depends on MCs, 
and both MCs and MDSCs are required for accelerated melanoma progression, 
providing a critical cellular link between BP180 dysfunction, pro-tumor 
microenvironment and tumor growth/metastasis.  
 
Our study not only highlights the possible anti-melanoma activity of BP180, but 
also points out the important role of basal keratinocytes in changing the tumor 
microenvironment. Inflammation is a hallmark of cancers; however, most studies have 
been focused on tumor-driven inflammation. There have been limited reports showing 
that inflammation triggered by untransformed cells may also play an important role in 
tumor progression. Our findings reveal that basal keratinocytes with BP180 dysfunction 
set the stage to recruit MCs and MDSCs, shaping a pro-melanoma microenvironment. 
To our knowledge, this is the first report showing that basal keratinocytes directly 
participate in melanoma progression through modulating skin inflammation. In 
summary, we uncovered that the cell-cell matrix adhesion molecule BP180 also 
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functions as a key regulator of skin inflammation and inflammation-driven melanoma 
progression through MCs and MDSCs. Basal keratinocytes, when losing NC16A 
domain, are the cell source initiating pro-tumor microenvironment. How BP180 performs 
its anti-inflammation activity by directly and/or indirectly modulating necessary signaling 
pathways for production of MCs and MDSCs-recruiting mediators remains to be 
determined (Hamill et al. 2011)(Löffek et al. 2014) (Van den Bergh et al. 2012). With this 
new melanoma model, further elucidating the role of BP180 in skin inflammation at 
molecular level will help better understand the mechanisms of melanoma progression 
for development of new therapeutic strategies for the disease. 
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2.5 MATERIALS AND METHODS 
Generation of Mice  
To study the immunopathogenesis of BP using autoantibodies from BP patients, 
we previously generated a humanized NC16A mouse strain on the C57BL/6J 
background (termed NC16A mice or WT mice) (Fig. 2.1A) (Liu et al. 2008). Exons 18 
and 19 (red) encoding the NC16A domain are flanked by loxP sites. When crossed with 
Cre mice (on C57BL/6J background, The Jackson Lab), Cre recombination removes the 
loxP-flanked exons 18 and 19 and maintains the remaining reading frame, resulting in 
mice expressing NC16A domain-truncated BP180 (this whole body deleted NC16A 
mice were termed ΔNC16A mice).   
 
To generate skin-specific ΔNC16A mice, NC16A mice were crossed with UBC-
Cre-ERT2 mice (Jackson Lab #008085) provided kindly by Dr. Richard Weinberg from 
UNC-Chapel Hill. The TamCre-NC16A mice (ERCre+NC16Afl/fl mice) when treated 
topically with tamoxifen (Sigma, 25 μl of 10 mg/ml in 62% EtOH/sunflower oil mixture) 
become skin-specific ΔNC16A (skinΔNC16A) mice. To generate basal keratinocyte-
specific ΔNC16A mice (K14Cre/ΔNC16 or K14Cre+NC16Afl/fl), NC16A mice were 
crossed with Krt-14 promoter driven Cre mice provided kindly by Dr. Dennis Roop at 
University of Colorado at Denver (Jackson Lab #004782). To confirm the deletion of 
NC16A-encoding exons, tail DNA were analyzed by genomic DNA PCR. The deletion of 
the NC16A domain in the skin was confirmed by immunoblotting and indirect 
immunofluorescence using NC16-specific antibodies. To confirm that the deletion of 
NC16A induced by topical treatment of tamoxifen occurred only in the ear skin, DNA 
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and protein samples from the non-treated skin and several internal organs including 
bone marrow, spleen and thymus were analyzed by NC16A-specific PCR and 
immunoblotting. All the mice were bred and housed at the University of North Carolina 
at Chapel Hill Animal Facility. Animal care, breeding and experiments were conducted 
in accordance with the Institutional Animal Care and Use Committee (IACUC) at the 
University of North Carolina at Chapel Hill. 
  
Murine Melanoma Models with Flank and Ear Injection of B16 Melanoma Cells 
B16-F10 murine melanoma cell line was acquired from ATCC and cultured in 
DMEM media (Gibco) supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin. For flank injection model, 8 weeks old mice were injected 
subcutaneously (s.c) into the side flank with 1x105 cells in 100 μl of HBSS buffer. For 
ear injection model, B16 melanoma cells (1x106) was injected intradermally (i.d) into the 
ears of 8 weeks old mice in 20 μl of HBSS buffer. Tumor growth was monitored and 
tumor volume was measured with a digital caliper. Tumor volume was calculated using 
the following equation: ½ x (length) x (width) (width). Mice were terminated on 21 days 
after initial melanoma cell injection. Lymphatic metastasis was monitored by examining 
tumor growth on the draining lymph node of ears on the neck (Bobek et al. 2010).  
 
Myeloid cells depletion was accomplished by the intraperitoneal injection (i.p) of 
200mg of RB6-8C5 rat anti mouse Gr1 antibody (Biolegend 108402) as previously 
described (Van Deventer et al. 2010). Normal rat IgG at the same dose (Biolegend 
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400602) was used as control. The injection schedule was day-1, day 0 and then 
biweekly.  
 
Immunoblotting and Immunofluorescence 
  To detect full-length and NC16A truncated BP180 in the mouse skin by 
immunoblotting, skin protein extracts were probed with anti-NC16A IgG purified from a 
patient with BP (termed anti-NC16A antibody) and a home-made rabbit antibody against 
mouse BP180 noncollagen 1-3 (NC1-3) domains (termed anti-NC1-3 antibody) (Fig. 
2.1A). Anti-human (Southern Biotech) and anti-rabbit (Cell Signaling) HRP-conjugated 
antibodies were used for BP180 immunoblotting detection. To localize BP180 in the skin 
by indirect immunofluorescence, cryosections (7μm) of mouse skin were stained with 
anti-NC16A and anti-NC1-3 antibodies, followed by FITC-conjugated anti-human IgG 
and anti-rabbit IgG (Jackson ImmunoResearch), respectively. Infiltrating immune cells in 
the skin cryosection were identified by indirect IF using anti-CD3 (BioLegend, 
clone:17A2) for T cells, anti-Iy6G (BioLegend,clone:1A8) for neutrophils, or anti-MBP 
(Mayo Clinic Scottsdale) for eosinophils, followed by Alexa Fluor 488 Goat Anti-Rat IgG 
(Life Technologies; 1:1000 dilution) for 1hour at room temperature. 
 
Mast Cells Culture, Reconstitution, Identification and Quantification 
Mast cells were isolated from bone marrow of c-kit sufficient NC16A mice (WT) 
and cultured as described (Jense et al. 2006). MCs were reconstituted locally in the skin 
of c-kit W-sh/W-sh as described (Chen et al. 2001). Briefly, 1x106 of cultured MCs were 
47 
 
injected to the ear of TamCre-NC16A c-kit W-sh/W-sh mice. The MC reconstituted TamCre-
NC16A c-kit W-sh/W-sh mice were used for experiments 6 weeks after MC reconstitution.  
Skin MCs were identified by toluidine blue (TB) staining (Jense et al. 2006)(Chen et al. 
2001). To quantify the number of MC in the skin, ear skin sections were stained with TB. 
MC in five randomly selected areas per section in a high-power field (magnification 
×200) were counted and expressed as Mean + SE.  
 
RNA Isolation, q-RT-PCR and Microarray Analysis.  
Skin RNA was isolated from three age and sex matched NC16A (WT) and 
ΔNC16A (KO) mice. RNA extraction and purification were performed using RNeasy 
Fibrous Tissue Mini Kit (Qiagen, USA). Isolated RNA from skin were used for qRT-PCR 
for detection of NC16A and for whole transcriptome microarray analysis. The microarray 
was acquired from Agilent (Mouse Gene Expression 4x44K Microarray Kit) and 
performed by Microarray Core of University of North Carolina at Chapel Hill. Heat map 
analysis was performed using R.  
 
Cytokine Array Analysis 
Skin lysates from three age and sex matched Skin control (WT mice treated with 
tamoxifen) and skinΔNC16A (TamCre-NC16A mice treated with tamoxifen) mice were 
extracted with PBS and analyzed with Proteome Profiler Mouse Cytokine Array Kit, 
Panel A as recommended by the Manufacturer (R&D System, ARY006).    
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MPO Activity Assay 
Infiltrating granulocytic myeloid cells in the skin were quantified by measuring the 
enzymatic activity of the cell marker myeloperoxidase (MPO) (Chen et al. 2001). Briefly, 
skin samples were extracted by homogenization in an extraction buffer containing 0.1 M 
Tris-Cl (pH 7.6), 0.15 M NaCl, and 0.5% hexadecyl trimethylammonium bromide. MPO 
activity in the supernatants was measured by the change in optical density at 460 nm 
resulting from decomposition of H2O2 in the presence of o-dianisidine. MPO activity was 
then normalized with the protein concentrations of skin extract supernatants and 
expressed as mU/mg protein + SE.  
 
Analysis of the Infiltrating Inflammatory Cells in the Skin by Flow Cytometry 
Isolation, identification, and quantification of skin inflammatory cells were 
performed as described (Chen et al. 2002). Briefly, ear skin were obtained and rinsed in 
70% ethanol, and then were cut into 1x4-mm sheets and submerged in a 6-well plate 
containing RPMI 1640 with 25 mM HEPES, 10% heat-inactivated FBS and 
penicillin/streptomycin. The plate was incubated at 37°C for 4 hours at 5% CO2 
incubator. The cells spontaneously emigrating out of the skin sections were pooled for 
flow cytometry analysis. Cells were identified by characteristic size (forward scatter) and 
granulosity (side scatter) combined with Pacific Orange Dye staining to distinguish live 
and dead cells (Thermo Fisher). Antibody recognizing CD11b, Ly6G and Ly6C were 
also used for flow cytometry analysis (Biolegend).   
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Statistical Analysis 
The data are expressed as mean + SEM and were analyzed using the Student's 
t-test. A p value less than 0.05 was considered significant. 
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Fig. 2.1. BP180 dysfunction ΔNC16A mice develop spontaneous skin 
inflammation.  
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A, Humanized NC16 mice (WT) with NC16A-encoding exons 18 and 19 (red) flanked by 
loxP sites (9) were crossed with germline Cre mice, resulting in mice expressing NC16A 
truncated BP180 (termed ΔNC16A). Antibodies against NC16A or NC1-3 domain were 
used to distinguish the full-length or NC16A truncated BP180. B, Genomic DNA PCR 
analysis confirmed the absence of the NC16A-encoding exons in ΔNC16A mice. C, 
Immunoblotting of skin protein extracts detected a full-length BP180 in WT and a 
NC16A-truncated BP180 in ΔNC16A mice. D, Immunofluorescence (IF) of skin revealed 
that anti-NC16A antibody stained the BMZ of only WT skin, while anti-NC1-3 antibody 
stained the BMZ of both WT and ΔNC16A skin, confirming the NC16A-truncated BP180 
were also localized in the BMZ of ΔNC16A mouse skin (panel d). E, epidermis; D, 
dermis; arrows, BMZ.  E. Quantification of TB stained-MCs showed a significant 
increase of infiltrated MCs in the skinΔNC16A mice. F, Clinical examination found that 
ΔNC16A mice started to develop spontaneous skin inflammation at around 8 weeks 
after birth (panel b). Histological examination revealed an inflammatory infiltrate and 
epidermal hyperplasia in ΔNC16A mice (panel d). Lesional skin of ΔNC16A mice 
showed significantly increased infiltrating neutrophils (Ly6G positive, panel e and f), T 
cells (CD3 positive, panel g and h) and eosinophils (MBP positive, panel i and j) by 
indirect IF and mast cells by toluidine blue (TB) staining (panel k and l). *p< 0.05, 
Student’s t test; n =5. All the data are mean ± SE.  
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Fig. 2.2. ΔNC16A mice show significantly increased melanoma progression in both flank 
and ear injection models. Eight weeks old of WT and ΔNC16A mice were injected at the flank 
(A-C) or ear (D-F) with 1x105 or 1x106 B16 melanoma cells, respectively, and examined at 
different time points post injection. In the flank model, ΔNC16A mice developed significantly 
larger size of tumors (A), significantly increased tumor growth rate at day15 (B) and significantly 
reduced survival rate at day 15 post injection (C). In the ear model (D), ΔNC16A mice showed 
significantly faster tumor growth starting day 14 (E) and significantly increased rate of 
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developing neck lymphatic metastasis at day 21 post melanoma cell injection (F). *p<0.05, 
**p<0.01, Student’s t test, n=10. 
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Fig. 2.3. Skin- and basal keratinocyte-specific BP180 dysfunction are sufficient to 
promote B16 melanoma progression. A, TamCreNC16A mice were treated at the left 
ear with tamoxifen (red) and right ear with vehicle control (white). B16 melanoma cells 
(1x 106 cells) were injected into both tamoxifen- and vehicle-treated ears 10 days post 
tamoxifen treatment. At 21 days post melanoma injection, only the tamoxifen-treated 
ear developed local tumor and lymphatic metastasis. B, Tumor volumes in tamoxifen-
treated ears were significantly increased at 14 and 21 days post melanoma cell injection 
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compared to vehicle-treated ears. C, 66% of tamoxifen-treated ears also developed 
lymphatic metastasis as compared to 20% of vehicle-treated control at 21 days post 
injection. **p<0.01, Student’s t test, n=13. D-F, Ears of 8 weeks old basal keratinocyte-
specific ∆NC16A (K14∆NC16A) mice were injected with B16 melanoma cells (1x106 
cells) and monitored for 21 days. K14∆NC16A mice developed significantly larger 
tumors at day 21 (D), significantly increased tumor growth starting day 14 (E) and 
significantly increased metastasis rate (F) at day 21 post melanoma injection. *p<0.05, 
**p<0.01, Student’s t test, n=8. 
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Fig. 2.4. Mast cells are crucial for melanoma progression in ∆NC16A mice. A-B, 
Ears of WT, ΔNC16A, and MC-deficient TamCreNC16AWsh mice were topically treated 
with tamoxifen and examined 2 weeks later. H/E examination exhibited a significant 
decrease in skin inflammation in MC-deficient skinΔNC16A mice compared to 
skinΔNC16A mice 2 weeks post tamoxifen treatment (d vs. b) (A). Skin MPO activity 
assay showed significantly reduced infiltrating neutrophils in MC-deficient skinΔNC16A 
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mice compared to skinΔNC16A mice (B). C-D, Ears of WT, ΔNC16A, MC-deficient and 
tamoxifen-induced MC-deficient ΔNC16A mice were injected with B16 melanoma cells 
(1x 106 cells) and monitored for 21 days. Tumor size at day 21 (C) and tumor volume at 
days 14 and 21 (D) were significantly reduced in MC-deficient ΔNC16A mice compared 
to ΔNC16A mice. E-F, MC-deficient TamCreNC16AWsh mice were locally reconstituted 
with 1x106 MC/ear. The MC-reconstituted (and control) ears were topically treated with 
tamoxifen 8 weeks post MC reconstitution, and injected with B16 melanoma cells (1x106 
cells) 10 day later. MC reconstitution restored tumor size and neck metastasis at day 21 
(E) and tumor volume (F) in MC-deficient ΔNC16A mice similar to MC-sufficient NC16A 
mice.    
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Fig. 2.5. Whole body-, skin- and basal keratinocyte-specific ΔNC16A mice have 
increased infiltration of MDSCs in the skin. 
MDSCs in the skin of 8 week old WT, whole body ΔNC16A and basal keratinocyte-
specific ΔNC16A (K14Cre/ΔNC16A) mice were identified and quantified by flow 
cytometry. Skin control and skinΔNC16A mouse was prepared through 14 days post 
tamoxifen treatment on the ear of WT and TamCre-NC16A mice. Polymorphonuclear-
MDSCs (PMN-MDSCs) are CD11b+Ly6G+ Ly6Clow, while monocytic MDSCs (M-
MDSCs) are CD11b+Ly6G-Ly6C+. A. A significantly increased number of PMN-MDSCs 
(B) and M-MDSCs (C) are present in the skin of ΔNC16A, TamCreΔNC16A and 
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K14ΔNC16A mice compared to WT mice. **p<0.01, Student’s t test, n=4 for 
K14ΔNC16A, n=6 for all other groups. 
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Fig. 2.6. Mast cells and MDSCs are crucial for MDSC infiltration in ∆NC16A mice. 
MDSCs in the skin of 8 week old WT, skinΔNC16A, MC-deficient WT, MC-deficient 
skinΔNC16A and MC-deficient skinΔNC16A mice with local MC reconstitution were 
identified and quantified by flow cytometry. PMN-MDSCs are CD11b+Ly6G+ Ly6Clow, 
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while monocytic MDSCs (M-MDSCs) are CD11b+Ly6G-Ly6C+. A. Higher number of 
MDSCs are present in the skin of ΔNC16A and MC-reconstituted MC-deficient 
skinΔNC16A mice compared to WT mice and MC-deficient skinΔNC16A mice. MC 
reconstitution also restored significantly increased number of PMN-MDSCs (B) and M-
MDSCs (C) in MC-deficient skinΔNC16A mice similar to ΔNC16A mice. **p<0.01, 
Student’s t test, n=6. D-E, We found MDSC depletion (i.p. injection anti-Gr1 antibody) 
significantly reduce the tumor volume (A) and rate of developing neck metastasis (B) in 
skinΔNC16A mice. 
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Fig. 2.7. BP180 dysfunction in skin basal keratinocyte triggers MC infiltration into 
skin, which leads to MDSC promoted melanoma progression. 
Our current model suggests that BP180 dysfunction in skin basal keratinocytes, which 
leads to increased mast cells in skin. Mast cells promote the influx of MDSCs and lead 
to the enhanced progression of melanoma.  
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Fig. S2.1. Generation of skin-specific ΔNC16A mice. NC16A mice were crossed with 
Cre-ER mice to generate tamoxifen inducible Cre NC16A (TamCre-NC16A) mice. 
TamCre-NC16A mice, when treated topically with tamoxifen, become skin-specific 
NC16A deletion. A, qRT-PCR showed that NC16A mRNA level in the ear was reduced 
more than 90% 3 days after the Tamoxifen treatment. B, IF revealed that like intact 
BP180, the NC16A-truncated BP180 were also localized in the dermal-epidermal 
junction of tamoxifen treated mouse skin (panel d). C, Immunoblotting showed that the 
NC16A truncated BP180 was expressed in the mouse ear skin 10 days after Tamoxifen 
topical treatment.  
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Fig. S2.2. Skin-specific ΔNC16A is sufficient to promote skin inflammation. We 
found TamCre-NC16A mice started to develop spontaneous skin inflammation at 
around 2 weeks after tamoxifen topical treatment as showed by either visible skin lesion 
(panel a and b) and histological examination (panel c and d). In addition, we found there 
is a significant increase in the infiltration of inflammatory immune cells into the skin, 
which includes neutrophils (Ly6G positive, panel e and f), T cells (CD3 positive, panel g 
and h) eosinophils (MBP positive, panel i and j) and mast cells (Toluidine Blue staining 
positive, panel k and l).  
  
65 
 
 
Fig. S2.3. Myeloperoxidase (MPO) result indicated that ΔNC16A promote the 
influx of myeloid cells into skin. MPO result showed that there is a significant 
increase in the activity of MPO in the skin of ΔNC16A mice, which indicates there is a 
significant increase in the number of infiltrated MPO expressing myeloid cells in the skin 
of ΔNC16A mice. Also, skin local inducible ΔNC16A also have a significant increase of 
MPO compared to Tamoxifen treated-Cre negative control mice. This result indicates 
that BP180 dysfunction promotes the influx of myeloid cells through local skin 
microenvironment.  
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Fig. S2.4. ΔNC16A leads to the upregulation of proinflammatory cytokine in skin. 
Cytokine array result showed that the skin of ΔNC16A mouse has increased amount of 
multiple proinflammatory cytokines/chemokines, which includes: C5/C5a, G-CSF, IL-1β, 
CXCL1 (KC), CCL2, CCL3, CXCL2 (MIP-2), TIMP1 and TREM1.  
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Fig. S2.5. Generation of basal keratinocyte conditional K14Cre/ΔNC16A mice. A. 
NC16A (WT) mice were crossed with Krt 14-promoter driven Cre mice to generate basal 
keratinocyte conditional K14Cre/ΔNC16A mice. A. K14Cre/ΔNC16A mice carry both 
Cre gene and NC16A gene as examined by PCR. B. Immunoblotting showed that the 
NC16A truncated BP180 was expressed in the mouse skin of K14Cre/ΔNC16A. C. We 
found K14Cre/ΔNC16A mice started to develop spontaneous skin inflammation at 
around 8 weeks after birth as showed by either visible skin lesion (panel a and b) and 
histological examination (panel c and d). In addition, we found there is a significant 
increase in the infiltration of inflammatory immune cells into its skin, which includes 
neutrophils (Ly6G positive, panel e and f), mast cells (Toluidine Blue staining positive, 
panel g and h), T cells (CD3 positive, panel i and j) and eosinophils (MBP positive, 
panel j and k). 
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Fig.S2.6. Anti-Gr1 antibody mediated myeloid cell depletion significantly reduces 
Gr1 positive immune cells in the skin of ΔNC16A mice. Anti-Gr1 antibody or control 
antibody was injected to TamCre-NC16A mice two weeks after Tamoxifen treatment. IF 
result showed that myeloid cells are significantly reduced in the skin Gr1 antibody 
injected mice 24 hrs after antibody injection. 
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Table 2.1. The NC16AKO mice showed an increased  
expression of proinflammatory cytokines and chemokines which are  
associated with the proinflammatory tumor microenvironment 
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CHAPTER 3 
BP180 dysfunction triggers spontaneous skin inflammation in mice1 
3.1 OVERVIEW AND SIGNIFICANCE 
Overview 
BP180, also known as collagen XVII, is a hemidesmosomal component and 
plays a key role in maintaining skin dermal/epidermal adhesion. Dysfunction of BP180, 
either through genetic mutations in Junctional Epidermolysis Bullosa (JEB) or 
autoantibody in Bullous Pemphigoid (BP), leads to subepidermal blistering 
accompanied by skin inflammation. However, whether BP180 is involved in skin 
inflammation remains unknown. To address this question, we generated a BP180-
dysfunctional mouse strain and found that mice lacking functional BP180 (termed 
ΔNC16A) developed spontaneous skin inflammatory disease, characterized by severe 
itch, defective skin barrier, infiltrating immune cells, elevated serum IgE levels 
andincreased expression of thymic stromal lymphopoietin (TSLP). Severe itch is 
independent of adaptive immunity and histamine, but dependent on increased 
                                                          
 
1 My contributions: 
Bin-Jin Hwang designed the concept of this project, developed parts of experimental 
methodology, generated mouse lines and keratinocyte culture system, performed 
majority of the experiments, acquired and analyzed the data and participated in the writing 
and revising the manuscript. This chapter has been prepared to the following manuscript 
and is undergoing re-submission to the “Proceeding of the National Academy of Science 
of the United States of America”: 
Zhang Y, Hwang BJ, Liu Z, Lough K, Williams SE, Chen J, Burrette SW, Li N, Diaz L, 
Maureen S, Xiao S and Liu Z. 
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expression of TSLP by keratinocytes. Our data provide the first direct evidence showing 
that BP180 regulates skin inflammation independently of adaptive immunity, and BP180 
dysfunction leads to a TSLP mediated itch. The newly developed mouse strain could be 
a model for elucidation of disease mechanisms and development of novel therapeutic 
strategies for skin inflammation and BP180-related skin conditions.  
Significance Statement 
We generated a novel BP180 dysfunctional mouse model, the ∆NC16A mice. 
The ∆NC16A mice develop spontaneous skin inflammation with itch starting at eight 
weeks after birth. The itch and skin inflammation on the ∆NC16A mice is not dependent 
on adaptive immunity. We found ∆NC16A increased thymic stromal lymphopoietin 
(TSLP) secretion from basal keratinocytes. TSLP is a cytokine which plays a key role in 
triggering itchy sensation by binding to TSLP receptor on neurons. As the result of 
increased concentration of TSLP in skin, BP180 dysfunctional mice develop scratching 
behavior starting at around eight weeks after birth, accompanied with other classical 
hallmarks of skin inflammation, which includes the loss of skin barrier function, 
increased infiltration of inflammatory immune cells, epidermal hyperplasia and 
increased concentration of serum IgE. Those findings provide the first direct evidence 
that BP180 dysfunction triggers skin inflammation independent of adaptive immunity, 
and itch sensation through TSLP. 
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3.2 INTRODUCTION 
BP180, also known as collagen XVII, is an 180-kDa transmembrane glycoprotein 
of the hemidesmosome anchoring basal keratinocytes into the underneath basal 
membrane of the skin (Hammers and Stanley 2016). The intracellular region of BP180 
is linked to the intermediate filament network, and its extracellular portion is anchored 
into the basement membrane zone (BMZ) through interacting with extracellular matrix 
proteins (Hopkinson and Jones 2000)(Koster et al. 2003)(Margadant et al. 2008)(Has 
and Kern 2010). Dysfunction of BP180 by gene mutations can lead to junctional 
epidermolysis bullosa (JEB) (Bauer and Lanschuetzer 2003)(Intong and Murrell 2012), 
a sub-epidermal blistering disease in human. In the skin autoimmune subepidermal 
blistering disease bullous pemphigoid (BP), anti-BP180 autoantibodies attack and 
impair function of BP180 autoantigen in basal keratinocytes causing dermal-epidermal 
separation (Giudice et al. 1991)(Bernard et al. 1992)(Liu et al. 1994). Pathogenic anti-
BP180 autoantibodies mainly target the juxtamembranous noncollagenous NC16A 
domain (Leighty et al. 2007)(Liu et al. 2008). These findings in JEB and BP establish 
BP180 a key cell-cell matrix adhesion molecule in the skin. However, whether BP180 is 
involved in other pathological conditions is largely unknown.  
 
Both BP and JEB share some features of skin inflammation. BP is characterized 
by skin infiltration of immune cells, increased IgE and itch (Hammers and Stanley 
2016)(Amber et al. 2017). JEB is very rare genetic disease, and some JEB patients 
developed atopic dermatitis (AD), (Lapinski et al. 1998)(Sibaud et al. 2002). Snauwaert 
et al. found that itch occurred in 100% of the JEB patients in their study and patients 
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can have a combination of JEB and AD in the clinic (Snauwaert et al. 2014). To 
determine whether BP180 is involved in skin inflammation, we generated a BP180 
dysfunctional mouse model (ΔNC16A), which developed a severe skin inflammatory 
condition with itch. The inflammatory condition and itch sensation on ΔNC16A mice are 
neither dependent on histamine nor adaptive immunity, which was suggested by a 
previous report (Hurskainen et al. 2014). Furthermore, we found that ΔNC16A 
increased the secretion of TSLP from keratinocytes and the concentration of TSLP in 
skin. TSLP plays a major role in skin inflammation and triggering itch (Wilson et al. 
2013)(Kumari et al. 2015). We found that the itch sensation triggered by BP180 
dysfunction depends on TSLP by injecting TSLP neutralizing antibody into ΔNC16A 
mice. To our knowledge, this is the first report demonstrating that BP180 dysfunction 
leads to skin inflammation independently of adaptive immunity, and linking BP180 
dysfunction with TSLP secretion. 
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3.3 RESULTS  
Generation of ΔNC16A Mice.  
Human and mouse BP180 lack immune cross-reactivity (Liu et al. 1993). To 
study the immunopathogenesis of BP using patients’ autoantibodies, we previously 
generated the humanized NC16A mice by replacing the mouse NC14A domain with the 
human NC16A counterpart (Liu et al. 2008). The NC16A domain is encoded by exons 
18 and 19, which were flanked by lox-P sites (Fig.3.1A). In this study, we use the 
humanized NC16A mice (NC16A mice) as wild-type (WT) control mice. When crossed 
with the germline Cre mice, Cre recombination removes the loxP-flanked exons 18 and 
19 and maintains the remaining reading frame, resulting in mice expressing NC16A 
domain truncated BP180 (termed ΔNC16A mice). Genotyping of mouse tail DNA 
confirmed the deletion of exons 18 and 19 in ΔNC16A mice (data not shown). Indirect 
immunofluorescence exhibited that anti-NC16A antibody stained the basement 
membrane zone (BMZ) of WT but not ΔNC16A mouse skin, while anti-NC1-3 antibody 
stained the BMZ of both WT and ΔNC16A mouse skin (Fig.3.1B). Immunoblotting 
showed that anti-NC16A antibody recognized full-length BP180 in WT mice but not in 
ΔNC16A mice, while anti-NC1-3 antibody recognized both WT and ΔNC16A mice 
(Fig.3.1C).  
 
ΔNC16A Mice Develop Spontaneous Dermatitis with itch.  
Most of the ΔNC16A mice showed no clinical skin phenotypes after birth but 
began to develop minor skin lesions at the age of 8 weeks and severe skin lesions at 12 
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weeks (Fig.S3.1A and Fig.3.1D). These ΔNC16A mice had overt skin inflammation, with 
eczematous lesions occurring mainly on the ears, eyelid, snout and dorsal skin 
(Fig.S3.1A and Fig.3.1D). Ear skin histology showed that ΔNC16A mice have marked 
acanthosis and prominent orthokeratosis with dermal inflammatory cell infiltration 
starting at 8 weeks after birth (Fig.S3.1A and Fig.3.1D). Low degree of dermal-
epidermal separation in the skin of adult ΔNC16A mice became evident at the age of 12 
weeks with increased inflammatory cell infiltration (Fig.S3.1A). The epidermal thickness 
of ΔNC16A mice was significantly increased compared to WT mice (Fig.S3.1B). 
ΔNC16A mice exhibited spontaneous itch, starting to show significantly increased 
scratching at 8 weeks after birth and reaching the plateau at 12-16 weeks after birth 
(Fig.S3.1C). These results indicate that BP180 dysfunction promotes spontaneous 
dermatitis with aberrant itch sensation.  
 
In addition, ΔNC16A mice exhibited a significant increase in serum IgE 
(Fig.S3.1D) and infiltrating inflammatory immune cells into the skin, including 
neutrophils (Fig.S3.2A), eosinophils (Fig.S3.2B), T cells (Fig.S3.2C) and mast cells 
(Fig.S3.2D). Whole transcriptome microarray of ΔNC16A ear skin tissue also showed 
that ΔNC16A mice exhibited a significant increase in the expression of genes 
associated with skin inflammation and dermatitis (Table 2.1), especially TSLP, IL-1β, IL-
13 that are typically increased in patients with skin inflammatory diseases (Leung 2011) 
(Fig.S3.3). The increased TSLP level of skin in ΔNC16A mice was also confirmed by 
ELISA assay (Fig.S3.2E). However, levels of TNFα, IFNγ and IL-4 were not significantly 
different between WT and ΔNC16A mice (Fig.S3.3). Because skin inflammation is also 
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correlated with barrier permeability (Leung 2011)(Dharmage et al. 2014), we also tested 
whether BP180 dysfunction may also reduce skin barrier function. Dye-exclusion assay 
on embryonic day E18.5 embryos showed that like WT mice, skin barrier of ΔNC16A 
mice was fully developed and intact before birth (Fig.S3.2F). However, the skin barrier 
of adult ΔNC16A mice was significantly impaired as determined by Evans blue dye 
(Fig.S3.2G) and fluorescein isothiocyanate (FITC) -conjugated albumin (BSA) 
permeability assay (Fig.S3.2H) respectively. Taken together, these results showed that 
ΔNC16A mice develop spontaneous skin inflammation and the symptoms including 
severe itch, increased serum IgE and reduced skin barrier function.   
 
Skin Local BP180 Dysfunction is Sufficient to Promote Skin Inflammation.  
BP180 is expressed in the skin as well as many other tissues (27). To determine 
whether the skin inflammation in ΔNC16A mice is caused by BP180 dysfunction locally 
in the skin and/or systemically, we developed tamoxifen inducible ERCre+NC16Afl/fl mice 
(termed TamCre-NC16A mice). When treated with tamoxifen topically, TamCre-NC16A 
mice become local skin-specific ΔNC16A (termed skinΔNC16A). The efficacy of NC16A 
deletion in skinΔNC16A mice was confirmed by qPCR (Fig.S4A) and immunoblotting 
(Fig.S3.4B). NC16A were identified in non-treated skin and several internal organs 
tested (data not shown). 
 
SkinΔNC16A mice started showing minor skin lesions and inflammation around 2 
weeks after a single tamoxifen treatment (Fig.3.2A and Fig.S3.4C). No skin lesions or 
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inflammation was seen in the ear of tamoxifen treated ERCre-NC16Afl/fl mice (Cre- 
control mice), ruling out the possibility that the skin inflammation was induced by 
tamoxifen itself (Fig.3.2A and Fig.S3.4C). Similar to whole body ΔNC16A, the 
skinΔNC16A mice also showed skin inflammation, including epidermis hyperplasia (Fig. 
3.2B), severe itch (Fig.3.2C), a significantly increased IgE level in serum (Fig.3.2D) and 
a significant increase in infiltrating neutrophils, eosinophils, T cells, and mast cells (Fig. 
3.2A, Fig.S3.5A-D and Fig.3.2E). SkinΔNC16A mice also showed a significantly 
increased skin TSLP level by ELISA assay (Fig.3.2F). SkinΔNC16A mice showed 
defective barrier function by Evans blue dye and FITC-conjugated BSA permeability 
assays as compared to control mice (Fig.S3.5E and F). These results demonstrated 
that similar to whole body ΔNC16A mice, ΔNC16A in the local skin is sufficient to 
develop skin inflammation.  
 
BP180 is expressed in many organs, including skin, ocular conjunctiva, epithelial 
basement membrane of the cornea, upper esophagus, transitional epithelium of the 
bladder, and brain (27). To investigate whether BP180 dysfunction triggers skin 
inflammation through basal keratinocytes, we generated basal keratinocyte-specific 
ΔNC16A mice (termed K14Cre/ΔNC16A). NC16A deletion was confirmed using western 
blot (Fig.3.3A). Similar to whole body ΔNC16A and skinΔNC16A mice, K14Cre/ΔNC16A 
mice also exhibited similar spontaneous dermatitis with significantly increased itchiness 
(Fig.3B) and immune cell infiltration (including neutrophils, T cells, eosinophils, and 
mast cells) (Fig.S3.6 and Fig.3.3C). Therefore, BP180 dysfunction in basal 
keratinocytes is sufficient to promote skin inflammation. 
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Skin Inflammation Occurs In ΔNC16A Mice in the Absence of Adaptive Immunity.  
Two hypotheses concerning the mechanism of skin inflammation have been 
proposed: one hypothesis proposes that the primary defect resides in an immunologic 
disturbance that causes skin inflammation; the other hypothesis proposes that an 
intrinsic defect in the epithelial cells (for example, keratinocytes) leads to skin 
inflammation (Bieber 2008)(Pasparakis et al. 2014). To assess whether adaptive 
immunity plays a major role in the spontaneous skin inflammation in our model, we 
crossed the ΔNC16A mice with T cell- and B cell-deficient Rag1-/- mice to generate 
adaptive immunity-deficient ΔNC16A (termed Rag1-/-ΔNC16A) (Fig.S3.7A and B). Rag1-
/-ΔNC16A and ΔNC16A mice were then compared for development of skin inflammation 
at 4, 8, and 12 weeks old (Fig.S3.7C). Rag1-/-ΔNC16A and ΔNC16A mice developed 
the same degree of skin inflammation including skin lesion, increased epidermal 
hyperplasia, increased infiltration of neutrophils, eosinophils, and mast cells into the 
dermis (Fig.3.4A and Fig.S3.7C) and itch (Fig.3.4B). Similar to ΔNC16A mice, TSLP 
levels were significantly increased in the lesional skin of Rag1-/-ΔNC16A mice 
(Fig.3.4C). In addition, Rag1-/-ΔNC16A also showed a defective skin barrier similar to 
ΔNC16A mice (Fig.S3.7D and E). To confirm these findings, we also generated 
tamoxifen skin inducible Rag1-/-TamCre-NC16A mice. Tamoxifen induced Rag1-/-
ΔNC16A mice also developed the same degree of skin inflammation as whole body 
Rag1-/-ΔNC16A and ΔNC16A mice (data not shown). These results suggest that 
adaptive immunity plays a minimal role in skin inflammation in ΔNC16A mice.  
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Itching in ΔNC16A Mice is Independent on IgE and Histamine but Dependent on 
TSLP.  
 
Itch in skin inflammation is orchestrated by the complex interplay of numerous 
mediators (Ikoma et al. 2006)(Bautista et al. 2014).ΔNC16A mice also exhibited 
significantly elevated IgE levels; but, Rag1-/-ΔNC16A, which lack antibodies, and 
ΔNC16A mice showed similar degree of itch, strongly suggesting that IgE is not 
involved in the itch phenotype. To further support this conclusion, B cell-deficient 
ΔNC16A mice (Ighmtm1cgnΔNC16A) were generated and examined for itch (Fig.S3.8). 
ΔNC16A mice lacking B cells, hence lacking IgE, still showed the spontaneous pruritic 
skin inflammation and increased level of TSLP similar to ΔNC16A mice (Fig.3.5A and B 
and Fig.S3.8).  
 
Induction of itch can be generally divided into two categories: histaminergic and 
non-histaminergic (Papoiu et al. 2012). We measured serum histamine level of 
ΔNC16A, K14Cre/ΔNC16A and WT mice, and found no difference between these three 
groups of mice (Fig.3.5C). We then used antagonists of the histamine receptors H1R 
and H4R, two HRs expressed and identified as potential mediators of pruriproception in 
the skin (Roßbach et al. 2009). Neither separate nor concomitant blockade of H1R and 
H4R resulted in significant reduction of scratching in ΔNC16A mice (Fig.3.5D). 
Therefore, these results suggest that itch in ΔNC16A mice is independent on IgE and 
histamine.   
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Numerous studies have reported that TSLP acts as a master switch of skin 
inflammation (Ziegler 2012)(He et al. 2008)(Zhang and Zhou 2012). We found that both 
concentration of TSLP and the number of scratches were significantly increased in 
skinΔNC16A (Fig.3.2F) and ΔNC16A lacking both T and B cells (Rag1-/-) and B cells 
(Ighmtm1cgn) (Fig.3.4C and 5B). To determine whether TSLP is required for itch in 
ΔNC16A mice, TSLP neutralizing antibody and control antibody were injected into the 
ear of skinΔNC16A mice 2 weeks post tamoxifen treatment. Anti-TSLP antibody 
treatment reduced scratching in ΔNC16A mice compared to control antibody (Fig.3.5E). 
Taken together, these results suggest that TSLP but not IgE or histamine pathway is the 
mechanism underlying severe itch in ΔNC16A mice. 
 
ΔNC16A Promotes the Release of TSLP From Keratinocyte in vitro.  
TSLP is expressed predominantly by epithelial cells in the thymus, lung, skin, 
intestine, and tonsils as well as stromal cells and mast cells but is not found in most 
hematopoietic cell types and endothelial cells. Our data showed that dysfunction of 
BP180 can induce the expression of TSLP even in the absence of T cells, B cells 
(Fig.3.4C) and mast cells (data not shown). Increased TSLP was seen in both 
skinΔNC16A and K14Cre/ΔNC16A mice, suggesting that keratinocytes could be the 
cellular source of TSLP production. To test if this is the case, we generated WT and 
ΔNC16A mouse primary keratinocyte cultures and compared their capacity of producing 
and releasing TSLP. ΔNC16A keratinocytes stimulated with mouse TNFα showed a 
significantly increased TSLP level in cell culture medium compared to WT keratinocytes 
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(Fig.3.5F). These data supported that BP180 dysfunction promotes the release of TSLP 
by keratinocytes. 
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3.4 DISCUSSION 
BP180 is well documented as a key cell-cell matrix adhesion molecule in the 
skin; however, other biological functions remain largely unknown (27). BP180 mutations 
lead to the partial or complete BP180 functional loss, which cause most commonly non-
Herlitz JEB (Fine 2010)(Kiritsi et al. 2011). From a study based on 43 European JEB 
patients with BP180 mutations, the patient group exhibited a wide clinical variability, 
from mild to severe phenotypes (Kiritsi et al. 2011). In general, the milder forms of JEB 
is associated with missense or splice-site mutations and the presence of truncated 
BP180 protein in skin (Kiritsi et al. 2011). In this study, we generated a mouse model 
with the deletion of NC16A domain (termed ΔNC16A mice). Because our ΔNC16A mice 
still express a truncated form of BP180, we consider ΔNC16A mouse as a BP180 
dysfunctional mouse model. ΔNC16A mice developed severe spontaneous skin 
inflammation characterized by immune cell infiltration, increased concentration of IgE 
and TSLP, itch and defective skin barrier. We further showed that the skin inflammation 
in ΔNC16A mice is caused by NC16A domain deletion in basal keratinocytes since skin- 
and basal keratinocyte-specific ΔNC16A mice phenocopy ΔNC16A mice. These 
findings suggest that BP180 also plays an important role in regulation of skin 
inflammation.  
 
Dysfunction of BP180 can be caused by BP180 gene mutations in JEB or anti-
BP180 autoantibody in BP (Bauer and Lanschuetzer 2003)(Liu et al. 1994). JEB is a 
rare autosomal recessive disorder caused by defects in any one of 6 genes including 
BPAG2, LAMA3, LAMB3, LAMC2, ITGB4 and ITGA6 which encode the 
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hemidesmosomal proteins BP180, laminin-332 and integrin α6β4, respectively (Intong 
and Murrell 2012)(Ng et al. 2012)(Sawamura et al. 2010). Patients with JEB develop 
subepidermal blisters within the lamina lucida of the BMZ, and itch is one of the most 
bothersome symptoms in JEB (Snauwaert et al. 2014)(Cohn and Teng 2016). Case 
reports indicate that JEB patients with BP180 gene mutations show increased itch and 
skin inflammation (Mabuchi et al. 2007)(Cifuentes et al. 2013). BP is the most common 
skin autoimmune blistering disease characterized by inflammatory cell infiltration, anti-
BP180 IgG and IgE and itch (Amber et al. 2017). Some rare childhood BP cases shared 
some clinical similarity with AD (Kamiya et al. 2016)(Kuenzli et al. 2004) and patients 
can suffer from AD and BP at the same time (Kamiya et al. 2016). Taken together, 
these clinical observations, previous animal-model-studies and our BP180 dysfunctional 
mouse models suggest that dysfunction of BP180 can lead to skin inflammation. 
 
Persistent itch is the most important symptom in skin inflammatory diseases. 
Some JEB patients suffer from severe itch with influx of pro-inflammatory cells into the 
skin (Snauwaert et al. 2014). Transmission of itch can be divided into two categories: 
histaminergic and non-histaminergic (Papoiu et al. 2012). Both histamine receptors, 
H1R and H4R, have been identified as potential mediators of pruriproception in the skin 
(Roßbach et al. 2009). We also rule out the histamine-dependent pathway as a cause of 
severe itch in ΔNC16A mice by showing that ΔNC16A mice did not have increased 
histamine levels (Fig.5C), and blockade of H1R and H4R did not reduce severity of itch 
in ΔNC16A mice (Fig.5D).  
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Recent work has highlighted TSLP in various inflammatory diseases, including 
skin inflammation (Zhang and Zhou 2012). TSLP is highly expressed in acute and 
chronic lesions in patients with skin inflammation (Soumelis et al. 2002). A mutation that 
increases TSLP expression in the skin has direct consequences on the development of 
a severe atopic disease in both humans and mice (Briot et al. 2009). Interestingly, 
cytokines which are commonly found at high levels in lesional skin of patients with skin 
inflammation, including IL-1β, TNFα, IL-4 and IL-13, can synergize to induce TSLP 
expression by keratinocytes (Leung 2011), suggesting a positive feed-back loop to 
amplify inflammation and itch. Significantly increased levels of TSLP (Fig. 2F, 4C, 5B 
and Fig.S3.2E), IL-1β and IL-13 (Fig.S3.3) were present in the skin of ΔNC16A mice, 
which correlated with severity of itch. More importantly, blockade of TSLP activity using 
TSLP neutralizing antibody reduced scratching in ΔNC16A mice (Fig.3.5E). Thus, TSLP 
in the skin is required for causing severe itch in ΔNC16A mice.     
  
TSLP is primarily expressed by epithelial cells in the gut, lungs, ocular tissue, 
thymus, epidermal keratinocytes in the skin, and also some other types of cells, such as 
mast cells, cancer cells, basophils and dendritic cells (DCs) (Ziegler 2012). Epithelial 
cells directly communicate to cutaneous sensory neurons via TSLP to promote itch 
(Wilson et al. 2013). Some cytokines, such as TNFα and IL1β, can induce TSLP 
secretion from keratinocyte (Kumari et al. 2015). We rule out T and B cells as a cellular 
source of TSLP since Rag1-/-∆NC16A mice show no change in skin TSLP levels and 
itch (Fig.3.4C). Both whole body and basal keratinocyte-specific ΔNC16A mice show 
significantly increased TSLP and itch. ΔNC16A primary keratinocytes produce and 
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release significantly more TSLP compared to normal control keratinocytes when 
stimulated with TNFα (Fig.3.5F). These in vivo and in vitro results suggest that basal 
keratinocytes are the cellular origin of the increased TSLP, which initiates of chronic itch 
caused by BP180 dysfunction. However, it is still unclear how BP180 dysfunction 
promotes the increased expression and secretion of TSLP from keratinocytes. Our 
future study will address this important issue. 
 
Previously, another group also generated BP180 dysfunctional mice termed 
ΔNC14A mice (Hurskainen et al. 2014). The ΔNC14A mice also show an increase in 
scratching behavior, eosinophil influx into skin and increased concentration of serum 
IgE (Hurskainen et al. 2014). However, the authors did not identify the exact mechanism 
to explain how BP180 dysfunction lead to the phenotypes they observed. Because 
increased IgE was found in the ΔNC14A mice, the authors proposed that BP180 
dysfunction may trigger autoimmunity which leads to skin inflammation (Hurskainen et 
al. 2014). Our ∆NC16A mice also show significantly elevated IgE (Fig.S3.1D and 
Fig.3.2D), and itch (Fig.S3.1C, Fig.3.2C and 3B), accompanied with an increased 
number of infiltrated T cells in the lesional skin (Fig.3.2A and 3C, Fig.S2C, S5 and S6). 
Because adaptive immunity has been considered as a key factor in the development of 
skin inflammation (Pasparakis et al. 2014)(Bieber 2008), it is possible that the 
components of adaptive immunity may play a role in the skin inflammation triggered 
BP180 dysfunction, including IgE. This possibility was tested by the Rag1-/-ΔNC16A and 
B cell-deficient ΔNC16A mice. Even though both mice lack IgE, they continue to scratch 
and develop skin inflammation as much as ΔNC16A mice (Fig.4 and 5A, Fig.S3.8).    
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Therefore, we ruled out that the increased IgE or any component of adaptive immunity 
is the cause of severe itch in ΔNC16A mice. These findings also suggest that T and B 
cells are not required for spontaneous skin inflammation in ΔNC16A mice, and local 
deficiency of BP180 function in basal keratinocytes is necessary and sufficient to drive 
skin inflammatory pathology.  
 
In summary, we developed a novel BP180 dysfunctional (ΔNC16A) mouse model 
to investigate the role of BP180 in vivo. Our results demonstrate that BP180, a cell-cell 
matrix adhesion molecule of the hemidesmosome, plays an important role in regulating 
skin inflammation. Dysfunction of BP180 in basal keratinocytes leads to increased TSLP 
expression, itch, immune cell infiltration, and defective skin barrier. Our findings provide 
evidence, supporting that JEB patients may have a higher risk to develop skin 
inflammation with itch (Mabuchi et al. 2007)(Cifuentes et al. 2013). Our animal model 
could also provide a new research angle for better understanding the skin inflammatory 
disease mechanisms related to BP180 dysfunction. Future investigations to elucidate 
the regulatory pathways underlying the molecular link between BP180 and skin 
inflammation should help identify new therapeutic targets for skin inflammatory diseases 
associated with altered BP180 expression.    
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3.5 MATERIALS AND METHODS 
 
Generation of Mice with Whole Body, Skin- and Basal Keratinocyte-Specific 
Deletion of NC16A. 
 
To study immunopathogenesis of BP using autoantibodies from BP patients, we 
previously generated a humanized NC16A mouse strain on the C57BL/6J background 
(termed NC16A mice or WT mice)(Liu et al. 2008). Exons 18 and 19 (red) encoding the 
NC16A domain (red) are flanked by loxP sites. When crossed with Cre mice (on 
C57BL/6J background, The Jackson Lab), Cre recombination removes the loxP-flanked 
exons 18 and 19 and maintains the remaining reading frame, resulting in mice 
expressing NC16A domain-truncated BP180 (this whole body deleted NC16A mice 
were termed ΔNC16A mice).   
 
To generate skin-specific ΔNC16A mice, NC16A mice were crossed with UBC-
Cre-ERT2 mice (Jackson Lab #008085) provided kindly by Dr. Richard Weinberg from 
UNC-Chapel Hill. The TamCre-NC16A mice (ERCre+NC16Afl/fl mice) when treated 
topically with tamoxifen (Sigma, 25 μl of 10 mg/ml in 62% EtOH/sunflower oil mixture) 
become skin-specific ΔNC16A mice. To generate basal keratinocyte-specific ΔNC16A 
mice (K14Cre/ΔNC16 or K14Cre+NC16Afl/fl), NC16A mice were crossed with Krt-14 
promoter driven Cre mice provided kindly from Dr. Dennis Roop at University of 
Colorado at Denver (Jackson Lab #004782). T and B cell-deficient mice (Rag1-/- mice, 
Jackson Lab) and B cell-deficient mice (B6.129S2-Ighmtm1Cgn/J mice, Jackson Lab 
#002288) were crossed with ΔNC16A mice to generate in house Rag1-/-ΔNC16 mice 
and B cell-deficientΔNC16 mice (Ighmtm1CgnΔNC16), respectively. To confirm the 
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deletion of NC16A-encoding exons, tail DNA was analyzed by genomic DNA PCR. The 
deletion of the NC16A domain in the skin was confirmed by immunoblotting and indirect 
immunofluorescence using NC16A-specific antibodies. To confirm that the deletion of 
NC16A induced by topical treatment of tamoxifen occurred only in the ear skin, DNA 
and protein samples from the non-treated skin and several internal organs including 
bone marrow, spleen and thymus were analyzed by NC16A-specific PCR and 
immunoblotting.  
 
All the mice were bred and housed at the University of North Carolina at Chapel 
Hill Animal Facility. Animal care, breeding and experiments were conducted in 
accordance with the Institutional Animal Care and Use Committee (IACUC) at the 
University of North Carolina at Chapel Hill.    
 
Detection of T cells, Neutrophil, Eosinophil and Mast Cells.  
The skin sample was frozen in Tissue-Tek OCT, and cryostat sections were air-
dried, blocked with PBS containing 10% of normal goat serum for 5mins and then 
stained with anti-CD3 (BioLegend, clone:17A2, 1:500 dilution) for T cells, anti-Iy6G 
(BioLegend,clone:1A8,1:1000 dilution) for neutrophils, or anti-MBP (Mayo Clinic 
Scottsdale, 1:500 dilution) for eosinophils for 1hour at room temperature followed by 
Alexa Fluor 488 Goat Anti-Rat IgG (Life Technologies; 1:1000 dilution) for 1hour at 
room temperature. 
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To quantify the number of mast cells in the skin, ear skin sections were stained 
with toluidine blue (TB) (Chen et al. 2001).The mast cells of at least five randomly 
selected areas per section in a high-power field (magnification ×200) were counted in 
the upper dermis and expressed as Mean + SE.  
 
Itch Quantification.  
The frequency of scratching behavior was measured by video-taping for a 15-min 
period. Licking of the belly and dorsal skin during grooming was disregarded, and only 
back feet moved across the face are counted. Each occurrence of the back foot 
scratching the neck, ear and nose were counted and used for statistical analysis (Higa 
et al. 2003).  
 
Histamine EIA Quantification and Histamine Receptor Blockade.  
Histamine levels in skin tissue and serum samples were quantified by a 
histamine enzyme immunoassay kit (Bertin Pharma), following the procedure described 
by the manufacturer’s instructions. To block histamine activity, histamine 1 receptor 
(H1R) antagonist (Olopatadine, 3 mg/kg) and/or histamine 4 receptor (H4R) antagonist 
(JNJ7777120, 30 mg/kg) in 0.5% carboxyl methyl-cellulose were administrated orally 
(Roßbach et al. 2009). Both antagonists were obtained from Sigma, USA. Mice were 
videotaped for 15 min before and after HR blocking to quantify changes in number of 
scratches. 
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Measurement of TSLP and TSLP Blockade.  
TSLP levels in skin lysate, serum, and supernatants of cell culture were detected 
and quantitated by using the mouse ELISA kit (R&D). To block TSLP activity in the skin, 
skinΔNC16A mice with severe itch were injected at both ears with 20 ug of neutralizing 
TSLP antibody (Biolegend, cat# 515202) or IgG2a control antibody (in 20 ul of PBS, 
Santa Cruz) (He et al. 2008). The mice were videotaped for scratching for 15 minutes 
right before and one hour after antibody injection.   
 
Keratinocyte Culture.  
Primary keratinocyte isolation and culture were described before (Williams et al. 
2011). Briefly, keratinocytes were isolated from the skin of TamCre-NC16A neonatal 
mice 48 hours after birth and maintained in E medium with 15% FBS and 50 μM 
CaCl2 (low Ca2+ medium). E medium is in house produced and provided by Dr. Scott E 
Williams from UNC-Chapel Hill (Williams et al. 2011). To generate ΔNC16A 
keratinocyte culture, keratinocytes isolated from TamCre-NC16A mice were treated with 
4-Hydroxytamoxifen (4OHT, 125 ng/ml), while the non-treated keratinocytes isolate from 
TamCre-NC16A were used as WT control. After 4OHT treatment, ΔNC16A 
keratinocytes were passaged in regular keratinocyte culture media and NC16A deletion 
was confirmed by PCR. Both WT and ΔNC16A keratinocytes were stimulated with 
mouse TNFα (0-10 ng/ml in PBS). Supernatants were collected 12 hrs and 24 hrs after 
TNFα stimulation.  
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Epidermis hyperplasia.  
The thickness of the ear skin was measured with a digital caliper (Fowler). For 
each mouse, 4 different sites of the ear were measured and an average thickness was 
calculated. Ear tissues were collected and fixed in 10% formalin solution, and then 
embedded in paraffin and cut into slices. Sections were stained with the hematoxylin-
eosin solution and photographed by a light microscope (Zeiss). The thickness of the 
epidermis was measured with Adobe Photoshop software; and the mean of at least 15 
randomly selected sections was calculated for each group.  
 
Measurement of total serum IgE by ELISA.  
Serum samples were taken at 4, 8 and 12 weeks after birth by heart puncture 
followed by centrifugation at 3000 g for 10 min at 4℃. The total IgE in mouse serum was 
measured by using the mouse ELISA kit (Mouse IgE ELISA MAXTM Deluxe, Bio-
Legend). 
 
Toluidine blue penetration assay of whole mouse embryos (E18.5). 
Heterozygotes NC16A+/- mice were bred and E18.5 embryos were isolated from 
pregnant mice. Isolated embryos were dehydrated with chilled methanol, and then 
stained by immersing in 0.1% toluidine blue (TB) solution. TB stained embryos were 
then washed with PBS to remove excessive staining before pictures were taken 
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(Hardman et al. 1998)(Wallace et al. 2012). Tail DNA were analyzed by PCR to identify 
genotype of each of the embryos after the toluidine blue penetration assay.  
 
Evans Blue dye penetration assay.  
For examining skin barrier function of adult skin, Evans Blue dye penetration 
assay was performed to detect barrier impairment. Mice were applied topically with 
Evans blue (1% in PBS, 50 ul/ear, Sigma). Two hours later mouse ear skin was 
collected and homogenized in formamide (Sigma). Retained amounts of Evans Blue 
with the skin were quantified by OD reading at 620 nm (Dreymueller et al. 2012)(Han et 
al. 2014). 
FITC-conjugated albumin (BSA) permeability assay.  
To assay the skin permeability for high molecular weight molecules, adult mouse 
ears were applied topically with FITC-conjugated BSA (0.5% in PBS, 25 ul/ear, Sigma), 
and 2 hours later fixed in 10% PBS-buffered formalin overnight. Fixed ear tissue was 
OCT embedded, sectioned and examined under a fluorescent microscope (Zeiss) to 
identify FITC-BAS in the skin (Howie et al. 2001).  
 
RNA isolation, q-RT-PCR and microarray analysis.  
Skin RNA was isolated from three NC16A (WT) and ΔNC16A (KO) mice, and all 
of them are age and sex matched. RNA extraction and purification were performed 
using RNeasy Fibrous Tissue Mini Kit (Qiagen, USA). Isolated RNA from skin were 
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used for qRT-PCR for detection of Nc16a, Il4, Il13, Ifn-γ, Tslp, Il1β, Tnfα, and for whole 
transcriptome microarray analysis (primer sequence for qRT-PCR are described in 
Supplemental Material and Method). The microarray was acquired from Agilent (Mouse 
Gene Expression 4x44K Microarray Kit) and performed by Microarray Core of University 
of North Carolina at Chapel Hill. Heat map analysis was performed using R.  
 
Statistical Analysis.  
The data were expressed as mean + SE and were analyzed using the Student's 
t-test. A p value less than 0.05 was considered significant. 
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Fig. 3.1. ΔNC16A mice exhibit skin inflammation with itch. (A) NC16A mice (WT) 
with NC16A-encoding exons 18 and 19 flanked by loxP sites were crossed with 
germline Cre mice, resulting mice expressing NC16A truncated BP180 (ΔNC16A). Anti-
NC16A and anti-NC1-3 antibodies recognize hNC16A and NC1-3, respectively. (B) 
Immunofluorescence (IF). Ear skin of WT and ΔNC16A mice were stained with anti-
NC16A and anti-NC1-3 antibodies. Anti-NC16A antibody stained the BMZ of only WT 
skin, while anti-NC1-3 antibody stained the BMZ of both WT and ΔNC16A skin. E, 
epidermis; D, dermis; arrows, BMZ. (C) Immunoblotting. Total skin protein extracts from 
WT and ΔNC16A mice were probed with anti-NC16A and anti-NC1-3 antibodies. Anti-
NC16A antibody recognized full-length BP180 in WT skin, while anti-NC1-3 antibody 
recognized both full-length and NC16A truncated BP180 in both WT and ΔNC16A skin. 
(D) ΔNC16A showed clinical skin lesion and hair loss around cheek, eyelid, and neck 
starting at 12 weeks old. H/E of ear skin revealed minor skin inflammation and minor 
101 
 
epidermal/dermal separation at 12 weeks old in ΔNC16A mice compared to WT mice. 
Original magnification, ×200.  
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Fig. 3.2. Skin-specific ΔNC16A (SkinΔNC16A) mice develop skin inflammation 
with increased immune cell infiltration, increased epidermal thickness, itch, 
serum IgE and TSLP. The ears of ERCre+NC16Afl/fl mice were topically treated with 
tamoxifen to induce SkinΔNC16A, while ERCre-NC16Afl/fl mice treated with tamoxifen 
were using as control mice. (A) The ears of skinΔNC16A mice started showing skin 
lesions clinically and histologically at 4 weeks after tamoxifen treatment compared to 
control mice (Cre-). Immune staining of ear skin also showed that skinΔNC16A mice 
have significantly increased infiltrating neutrophil, eosinophil and CD3 positive T cells at 
4 weeks post tamoxifen treatment. Original magnification, ×200. Toluidine blue (TB) 
staining indicated that there was a significant increase in mast cells skinΔNC16A mice 
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starting at 1 week post tamoxifen treatment (A and E). Original magnification, ×200. (B-
E) As compared to control mice (Cre-), skinΔNC16A mice (Cre+), increased epidermis 
thickness (B), increased spontaneous itch (C), increased serum IgE level (D), and TSLP 
(E) in skin starting at 2 weeks after tamoxifen treatment. *P < 0.05, Student’s t test; n = 
8. All the data are mean ± SE. 
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Fig. 3.3. Basal keratinocyte-specific ΔNC16A (K14Cre/ΔNC16A) mice exhibit skin 
inflammation. (A) Deletion of NC16A in K14Cre/ΔNC16A mice was confirmed by IB 
using anti-NC16A antibody. (B) K14Cre/ΔNC16A mice also exhibited a significant 
increase of scratching compared to WT mice starting at 8 weeks after birth. *P < 0.05, 
Student’s t test; n = 8 mice. All the data are mean ± SE. (C) As compared to WT control, 
K14Cre/ΔNC16A mice start showing clinical skin lesions, increased epidermal thickness 
by routine histology examination and increased infiltrating neutrophils, CD3+ T cells, 
eosinophils and mast cells by indirect immunofluorescence and toluidine blue staining at 
12 weeks old.  
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Fig. 3.4. ΔNC16A mice deficient of both T and B cells (Rag1-/-ΔNC16A) develop 
similar skin inflammation as whole body ΔNC16A mice. (A) Similar to ΔNC16A 
mice, Rag1-/-ΔNC16A mice developed skin lesion by clinical examination, epidermal 
hyperplasia and immune cell infiltration by H/E of ear skin, and increased infiltration of 
neutrophils, eosinophils and mast cells by indirect IF and toluidine blue staining at 12 
weeks old. (B-C) Rag1-/-ΔNC16A and ΔNC16A mice also exhibited similar degree of itch 
(B), and increased TSLP in skin (C). *P < 0.05, Student’s t test; n = 4-6 mice. All the 
data are mean ± SE. 
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Fig. 3.5. Itch in ΔNC16A mice is independent on IgE and histamine but dependent 
on TSLP by keratinocytes. (A) B cell- ΔNC16A mice as IgE-deficient mice exhibited a 
similar degree of itch as ΔNC16A mice. (B) B cell-deficient ΔNC16A mice showed an 
increased TSLP level similar to ΔNC16A mice. (C) Serum histamine levels in ΔNC16A, 
K14Cre/ΔNC16A and WT mice were similar determined by histamine immune assay. 
(D) ΔNC16A mice at 8 weeks old were administrated orally with H1R and H4R 
antagonist respectively. The blockade of H1R and/or H4R had no effect on itch. (E) 
TamCre-NC16A mice (ERCre+NC16Afl/fl) were treated topically at ear with tamoxifen to 
generate skinΔNC16A mice. Two weeks later, the ear of skinΔNC16A mice were 
injected with TSLP neutralizing antibody or IgG2a control antibody (20 ug/ear). The 
mice were videotaped right before and 1 h post antibody injection for 15 min. TSLP 
blockade significantly reduced itch in skinΔNC16A mice compared to the control 
antibody-treated skinΔNC16A mice. *p< 0.05, Student’s t test; n = 6 mice. (F) WT and 
ΔNC16A keratinocytes were stimulated with mouse TNFα for 12 and 24 h. ΔNC16A 
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keratinocytes released significantly higher amount of TSLP in culture medium that WT 
keratinocytes. *p< 0.05, Student’s t test; n =6. 
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Fig. S3.1. ΔNC16A mice exhibit skin inflammation with itch. (A) NC16A mice (WT) 
with NC16A-encoding exons 18 and 19 flanked by loxP sites (2) were crossed with 
germline Cre mice, resulting mice expressing NC16A truncated BP180 (ΔNC16A). Anti-
NC16A and anti-NC1-3 antibodies recognize hNC16A and NC1-3, respectively. ( (D) 
Clinical and histological examination. ΔNC16A showed clinical skin lesion and hair loss 
around cheek, eyelid, and neck starting around 8 weeks old and became more severe 
at 12 weeks old. H/E of ear skin revealed minor skin inflammation at 8 weeks old and 
minor epidermal/dermal separation at 12 weeks old in ΔNC16A mice compared to WT 
mice. Original magnification, ×200. As compared to WT mice, ΔNC16A mice, starting 8 
weeks old, exhibited a significantly increased epidermis thickness (B), significant 
increase in itch (scratch motion) (C), significantly increased serum IgE levels (D). *p< 
0.05, Student’s t test; n = 8-10. All the data are mean ± SE.  
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Fig. S3.2. ΔNC16A mice exhibit increased immune cell infiltration, TSLP level and 
defective skin barrier. Immune staining of ear skin showed that ΔNC16A mice started 
to have significantly increased infiltrating neutrophil (A), eosinophil (B) and CD3 positive 
T cells (C) starting at 8 weeks old. Original magnification, ×200. (D) Toluidine blue (TB) 
staining indicated that there was a significantly increase in the influx of mast cells into 
the skin of ΔNC16A mice starting at 8 weeks after birth. Original magnification, ×200. 
(E) ΔNC16A mice showed a significant increase of TSLP expression in ear skin starting 
8 weeks old compared to WT mice determined by ELISA. (F) Toluidine blue penetration 
assay showed no barrier defect in E18.5 embryos of ΔNC16A and WT mice. Adult 
ΔNC16A mice started to show a significant reduction in barrier function at 8~12 weeks 
after birth, by Even Blue (G) and FITC-conjugated BSA permeability assays (H). *p< 
0.05, Student’s t test; n = 8. All the data are mean ± SE. 
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Fig. S3.3. Quantification of cytokines at mRNA levels. mRNA levels of inflammatory 
cytokines in the skin of NC16A (WT) and ΔNC16A mice at 4, 8, and 12 weeks old were 
analyzed by quantitative RT-PCR (qRT-PCR). ΔNC16A mice showed significantly 
increased levels of TSLP (C), IL-13 (D) and IL-1β (E) compared to WT, while there were 
no significant difference between ΔNC16A (KO) and WT mice in IL-4 (A), IFN-γ (B), and 
TNFα (F).  
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Figure S3.4. Generation of skin-specific ΔNC16A (skinΔNC16A) mice. The ears of 
ERCre+NC16Afl/fl mice were topically treated with tamoxifen to induce SkinΔNC16A, 
while ERCre-NC16Afl/fl mice treated with tamoxifen were using as control mice. (A) The 
ears of skinΔNC16A mice started showing skin lesions clinically and histologically at 2 
weeks after tamoxifen treatment compared to control mice (Cre-). Deletion of NC16A 
was examined at 0-10 days post tamoxifen treatment. (B) Quantitative RT-PCR showed 
drastically reduction of full-length BP180 mRNA. mRNA from whole body ΔNC16A mice 
was used as control. (C) Immunoblotting of ear skin protein extract confirmed deletion of 
NC16A domain of BP180 in skin ΔNC16A mice using anti-NC16A antibody.  
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Fig. S3.5. SkinΔNC16A mice exhibit increased immune cell infiltration and 
defective skin barrier. The ears of ERCre+NC16Afl/fl mice were topically treated with 
tamoxifen to induce skinΔNC16A, while ERCre-NC16Afl/fl mice treated with tamoxifen 
were using as control mice. Immune staining of ear skin showed that skinΔNC16A mice 
have significantly increased infiltrating neutrophil (A), eosinophil (B) and CD3 positive T 
cells (C) starting at 1-2 weeks post tamoxifen treatment. Original magnification, ×200. 
Toluidine blue (TB) staining indicated that there was a significant increase in mast cells 
skinΔNC16A mice starting at 1 week post tamoxifen treatment (D). Original 
magnification, ×200. (E) Evans Blue dye penetration assay showed barrier defect in 
skinΔNC16A but not control mice starting 1 week post tamoxifen treatment. (F) FITC-
conjugated BSA permeability assays also revealed barrier defect in skinΔNC16A but not 
control mice starting 2 weeks post tamoxifen treatment. *p< 0.05, Student’s t test; n = 8. 
All the data are mean ± SE. 
113 
 
 
Fig. S3.6. Basal keratinocyte-specific ΔNC16A (K14Cre/ΔNC16A) mice exhibit skin 
inflammation. As compared to WT control, K14Cre/ΔNC16A mice start showing clinical 
skin lesions, increased epidermal thickness by routine histology examination and 
increased infiltrating neutrophils, CD3+ T cells, eosinophils and mast cells by indirect 
immunofluorescence and toluidine blue staining staring 8 weeks old. 
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Fig. S3.7. ΔNC16A mice deficient of both T and B cells (Rag1-/-ΔNC16A) develop 
similar skin inflammation as whole body ΔNC16A mice. ΔNC16A mice were 
crossed with Rag1-/- mice to generate Rag1-/-ΔNC16A mice. (A) Immunoblotting of ear 
skin protein extract using anti-NC16A antibody confirmed NC16A deletion in Rag1-/-
ΔNC16A mice. (B) Flow cytometry confirmed that CD3+T cell (G1) and CD19+B cell 
(G2) were absent in Rag1-/-ΔNC16A mice. (C) Similar to ΔNC16A mice, Rag1-/-ΔNC16A 
mice developed inflammatory skin lesion by clinical examination, epidermal hyperplasia 
and immune cell infiltration by H/E of ear skin, and increased infiltration of neutrophils, 
eosinophils and mast cells by indirect IF and toluidine blue staining starting at 8 weeks 
old. (D-E) Rag1-/-ΔNC16A and ΔNC16A mice also exhibited similar degree of barrier 
defect determined by Evans Blue penetration assay (D) and FITC-conjugated BSA 
permeability assays (E). n = 4-6 mice. All the data are mean ± SE. 
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Fig. S3.8. B cell-deficient ΔNC16A mice develop skin inflammation. ΔNC16A mice were 
crossed with B cell-deficient mice to generate B cell-deficient ΔNC16A mice. (A) NC16A 
deletion in B cell-deficient ΔNC16A mice was confirmed by immunoblotting using anti-NC16A 
antibody. (B) B cell-deficient ΔNC16A mice exhibited a similar degree of itch as ΔNC16A mice. 
(C) B cell-deficient ΔNC16A mice and ΔNC16A mice showed the same degree of increased 
epidermal thickness by H/E, infiltration of neutrophils, CD3+ T cells, eosinophils by indirect IF, 
increased mast cells by toluidine blue staining.  
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Table 2. Increased expression of proinflammatory cytokines in ΔNC16A mice. Skin 
RNA was isolated from three age- and sex matched NC16A (WT) and ΔNC16A (KO) 
mice (8 weeks old) and were used for whole transcriptome microarray analysis. 
Increased expression of proinflammatory cytokines and chemokines associated with 
dermatitis are listed. 
Agilent Microarray ID 
Name of Genes  
in dataset 
Exp Fold 
Change   
A_55_P1953169 Saa3 32.70    
A_55_P1998471 S100a9 17.89    
A_55_P2156697 Il17a 11.99    
A_55_P1990032 Cxcl5 9.02    
A_55_P1990032 Cxcl6 9.02    
AGI_MM_OLIGO_A_51_P217463 Cxcl2 8.11    
AGI_MM_OLIGO_A_51_P509573 Ccl4 7.00    
A_55_P2128144 Il19 5.40    
A_55_P2103249 Cxcr1 4.93    
AGI_MM_OLIGO_A_51_P363187 Cxcl1 4.58    
A_55_P2070869 Lcn2 4.34    
AGI_MM_OLIGO_A_51_P140710 Ccl3 3.62    
A_55_P1997756 Il6 3.08    
A_55_P1962209 Cxcr6 2.81    
A_55_P2165199 Cxcr6 2.62    
A_66_P132710 Il20 2.23    
AGI_MM_OLIGO_A_51_P378789 Cxcl13 2.12    
A_55_P1995537 Mpo 2.12    
A_55_P2147712 Ctla4 2.05    
A_55_P1994807 Saa1 2.04    
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A_66_P109708 Il36a 2.03    
A_55_P1984556 Ccl12 1.85    
AGI_MM_OLIGO_A_51_P464703 Ccl8 1.70    
AGI_MM_OLIGO_A_51_P461665 Cxcl9 1.61    
AGI_MM_OLIGO_A_52_P585124 Cxcr4 1.49    
AGI_MM_OLIGO_A_51_P385812 Il12b 1.27 
  
A_55_P2180839 Il13 1.17    
A_55_P2138386 Il5 0.57    
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CHAPTER 4. 
DISCUSSION AND FUTURE DIRECTIONS 
4.1 Summary and conclusions 
BP180 is a hemidesmosomal protein and functions mainly as a cell-ECM 
adhesion molecule. Other functions of BP180 are still largely unknown, and the reason 
lays with the high mortality rate of BP180 null mice (Nishie et al. 2007)(Hurskainen et al. 
2012). With the ∆NC16A mouse model, we generated a BP180 dysfunctional mouse 
which can live into its adulthood, up to 6 months after birth. . In addition, because the 
DNA sequence encoding NC16A is flanked with lox P sites, we are able to generate a 
variety of conditional and inducible ∆NC16A mice by crossing our NC16A (WT) mice 
with the mice carrying different promoter driven Cre. Therefore, our ∆NC16A mouse 
model provides an  invaluable tool to uncover new functions of BP180 in vivo 
(Hurskainen et al. 2012)(Nishie et al. 2007).  
 
In this study, we demonstrated a novel function of BP180, which is modulating 
skin inflammation through skin basal keratinocytes in vivo. Skin basal keratinocytes with 
BP180 dysfunction lead to an inflammatory microenvironment. We explored this 
inflammatory skin microenvironment in two different but related areas: 1) skin 
inflammation and itch; 2) tumor microenvironment and melanoma progression.  
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We found that BP180 dysfunction triggers a skin inflammation with increased 
mast cell (MC) influx, and the infiltrated MCs support the population of myeloid derived 
suppressor cells (MDSCs) in the inflamed skin. MDSCs promote the B16 progression 
most likely through immunosuppression; therefore, BP180 dysfunction eventually leads 
to increased melanoma progression in vivo. MC deficiency significantly reduces MDSCs 
population and MC reconstitution restores MDSCs population in BP180 dysfunctional 
mice. Tumor progression showed a similar pattern compared with MDSC infiltration in 
∆NC16A skin. In addition, antibody mediated MDSC depletion is sufficient to 
significantly reduce melanoma progression. For the first time, our results illustrate that 
BP180 dysfunction in skin basal keratinocytes leads to MC mediated MDSC 
accumulation in the affected skin area, and promotes melanoma progression (Figure 
4.1).  
 
We found ∆NC16A increased thymic stromal lymphopoietin (TSLP) secretion 
from basal keratinocytes. TSLP is a cytokine which plays a key role in triggering itchy 
sensation by binding to TSLP receptor on neurons (Bautista et al. 2014)(Jariwala et al. 
2011)(Wilson et al. 2013). As the result of increased concentration of TSLP in skin, 
BP180 dysfunctional mice develop scratching behavior starting at around eight weeks 
after birth. These findings provide the first direct evidence that BP180 dysfunction may 
cause skin inflammation through upregulation of SLP.  
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Figure 4.1. Summary and conclusion of my past research covered at Chapter 2 
and 3. The overall conclusion for my past research is that BP180 dysfunction in basal 
keratinocytes, leads to the increased accumulation of mast cells in skin. Increased 
amount of mast cells promote the influx of MDSCs, which eventually promote skin 
inflammation and melanoma progression.  
4.2 New understandings of BP180 in skin inflammation.  
The previous report also showed that BP180 dysfunction in mice (termed 
∆NC14A )  leads to skin inflammation, accompanied with increased serum IgE, 
scratching behavior and eosinophil influx into skin (Hurskainen et al. 2014). These 
phenotypes are shared with our ∆NC16A mouse model.  
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The ∆NC16A mouse model reflect some of the physiological aspects of human 
JEB, which is caused by the mutations on Col17a1, the gene encoded BP180 (Kiritsi et 
al. 2011). JEB is a rare autosomal recessive disorder affecting approximately 
8:1,000,000 in the human population (Fine et al. 2009). It is caused by defects in any 
one of at least 18 genes whose encoded proteins control the integrity of the dermal and 
epidermal layers (Fine 2010)(Sawamura et al. 2010)(Uitto et al. 2010)(Bruckner-
Tuderman and Has 2012). Mutation in Col17a1 leads to non-Herlitz type of JEB, with 
milder symptoms and its patients can survive into adulthood (Fine 2010)(Sawamura et 
al. 2010)(Uitto et al. 2010)(Bruckner-Tuderman and Has 2012). There is no known 
mutation hotspot in Col17a1 (Kiritsi et al. 2011). There are very few reported cases of 
JEB with BP180 mutation (around than 60 reported cases) (Kiritsi et al. 2011). To our 
knowledge, there is no report of JEB patients expressing truncated BP180 lacking the 
NC16A region. However, there are two cases reported indicating that JEB patients with 
mutations at BP180 show increased itch and skin inflammation, which are similar to the 
phenotypes observed in our ∆NC16A mouse model (Mabuchi et al. 2007)(Cifuentes et 
al. 2013). One of the case is a middle-age Japanese patient with insertion mutation on 
exon 5 of the gene encoded BP180 (Mabuchi et al. 2007). This man suffers significantly 
increased itch sensation and eosinophilia, and symptoms were significantly suppressed 
with oral steroid treatment (Mabuchi et al. 2007). There is another case report showing 
a 22 year old Turkish-German female with Col17a1 mutation (Cifuentes et al. 2013). 
This patient exhibited a significant increase in the level of IgE in serum, eosinophilia and 
itch (Cifuentes et al. 2013). Both cases show BP-like skin inflammation and share some 
similarity to our mouse model. Patients with JEB also suffer from chronic itch. BP had 
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been had been viewed both an inflammatory disease and autoimmune disease, and its 
symptoms included the influx of mast cells, neutrophils, eosinophils and itch (Leighty et 
al. 2007).  It was also reported that rare childhood BP cases shared some clinical 
similarity with atopic dermatitis (AD), which is a type of skin inflammatory disease, and 
were initially misdiagnosed as AD (Belhadjali et al. 2009)(Kuenzli et al. 2004). It was 
also reported that patients can suffers with AD and BP at the same time (Kamiya et al. 
2016). The reported cases above support the results from the ∆NC16A mouse model, 
indicating that BP180 dysfunction, no matter if it is due to genetic mutations or 
autoimmunity, can lead to skin inflammation.  
 
Two hypotheses concerning the mechanism of skin inflammation have been 
proposed:  one hypothesis proposes that the primary defect resides in the immune 
system with the local inflammation as consequence; the other hypothesis proposes that 
an intrinsic defect in the epithelial cells leads to skin inflammation (Bieber 2008). 
Because the ∆NC14A mouse model showed a significant increased serum IgE, it was 
proposed that BP180 dysfunction may leads to skin inflammation through adapt immune 
response, especially IgE (Hurskainen et al. 2014). However, we found skin inflammation 
is not dependent on adapt immunity by crossing the ∆NC16A mouse with T/B cells and 
B cells deficient mice. In addition, we found that NC16A deletion in local skin and basal 
keratinocytes are sufficient to trigger inflammation. Therefore, we conclude that BP180 
dysfunction leads to skin inflammation through epithelial keratinocytes, which is 
independent from adapt immunity. Further research is needed to investigate the 
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mechanism behind how BP180 dysfunction promotes skin inflammation through basal 
keratinocytes.   
 
4.3 New Function of BP180 in melanoma progression through skin basal 
keratinocytes 
 
Previous studies found that BP180 and its binding partners, which includes α6β4 
integrin and laminin 332, play a positive role in cancer cell adhesion and motility in vitro 
(Stewart and O’Connor 2015)(Van Den Bergh et al. 2011). However, it is unknown 
whether BP180 in skin basal keratinocytes plays a role in melanoma progression. 
Untransformed basal keratinocytes have been shown to inhibit melanoma metastasis 
and play a role in host defense against melanoma progression (Golan et al. 2015). 
Therefore, BP180 may play a role in keratinocytes against melanoma progression. To 
test this hypothesis, exogenous B16 melanoma tumor cells were injected in BP180 
dysfunctional mice.  Melanoma progression is significantly increased in BP180 
dysfunctional mice. In conclusion, our results show that BP180 plays a role in the 
melanoma microenvironment through untransformed basal keratinocytes, which is very 
different from the previous reports indicating that BP180 in cancer cells promotes the 
invasiveness of cancer cells (Stewart and O’Connor 2015)(Van Den Bergh et al. 2011). 
 
Our study not only highlights the possible role of BP180 in modulating the tumor 
microenvironment, but also points out the important role of skin, or more precisely, 
epidermal keratinocytes in the tumor microenvironment. Skin is known to be the largest 
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immune-protective organ in our body, and keratinocytes play a crucial role in modulating 
inflammation and defense against host infection in the skin (Di Meglio et al. 
2011)(Bangert et al. 2011). To our knowledge, there are very limited reports showing 
that keratinocytes may play a role in the tumor microenvironment (Golan et al. 
2015)(Van Kilsdonk et al. 2010). Further studies are needed to elucidate the anti-tumor 
role of untransformed keratinocytes in the progression of nearby cancer cells.   
 
Even though inflammation has been accepted as a hallmark of cancers, studies 
mostly focus on tumor-driven inflammation (Hanahan et al. 2011)(Crusz and Balkwill 
2015). There are very few reports showing that inflammation triggered by untransformed 
cells may also play a significant role in tumor progression. In addition, skin inflammation 
may play a crucial role in tumor progression (Tang and Wang 2016), which indicates 
that untransformed cells in skin may affect cancer progression through modulating 
inflammation. To our knowledge, this is the first report showing that basal keratinocytes 
may play a role in melanoma progression through modulating skin inflammation. Our 
study highlights that there is a need to investigate how skin keratinocytes and 
hemidesmosomal proteins may contribute to anti-tumor immune responses.  
 
Another question that remains unanswered in this dissertation is which subset of 
infiltrating MDSCs plays a more important role in promoting melanoma progression in 
∆NC16A mice?  MDSCs have two major subsets: Ly6G+Ly6C-  PMN-MDSCs, which 
may differentiate into tumor associated neutrophils (TAN); and Ly6G-Ly6C+ M-MDSCs, 
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which may differentiate into tumor associated macrophages (TAM) (Youn et al. 
2012b)(Youn et al. 2012a)(Talmadge and Gabrilovich 2013). Because the majority of 
MDSCs that migrate into the skin of ΔNC16A mice are PMN-MDSCs, we hypothesize 
that PMN-MDSCs may play the most significant role in tumor progression in ΔNC16A 
mice. It has been reported that CXCR2 plays an important role in the migration of PMN-
MDSCs (Jamieson et al. 2012)(Singh et al. 2009), similar to neutrophils. We tried to 
answer this question by generating TamCre-NC16A mice lacking the CXCR2 
chemokine receptor (termed TamCre-NC16ACXCR2-/- mice). To our surprise, even 
though we did observe  reduced skin inflammation on TamCre-NC16ACXCR2-/- mice, 
the tumor progression is not significantly reduced compared to CXCR2 sufficient 
TamCre-NC16A mice (Figure 4.2, n=8). One possible explanation for why CXCR2 
deficiency did not reduce the melanoma progression in ∆NC16A mice is that PMN-
MDSCs, unlike PMNs, do not totally depend on CXCR2 to migrate to the inflamed and 
tumor site. This possibility is supported by the fact that we still observed an abundant 
amount of Ly6G positive cells in the tumor of TamCre-NC16ACXCR2-/- mice. Because 
there is no surface marker to distinguish between the regular neutrophils and PMN-
MDSCs, it is also possible that neutrophils had been mistakenly characterized as PMN-
MDSCs in the previous report (Jamieson et al. 2012)(Singh et al. 2009), which may 
have led to the unreliable conclusion that CXCR2 played a key role in PMN-MDSC 
migration. This possibility is also supported by a recent report showing that CCL2, which 
binds to CCR2 and has long been considered the key chemoattractant for M-MDSCs 
and macrophages, also plays an important role in PMN-MDSC migration (Chun et al. 
2015).  
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Figure 4.2 CXCR2 deficiency did not significantly reduce the tumor progression in 
ΔNC16A mice. Immunofluorescence (IF) staining showed CXCR2 deficient (CXCR2-/-) 
skin∆NC16A mice still showed an increased Gr1+ immune cells infiltration in skin (A). 
B16 melanoma cells (1x106) was injected into the ear of CXCR2 sufficient (CXCR2+/+) 
and deficient skin control and skin∆NC16A mice. At 21 days post melanoma injection, 
CXCR2-/- and CXCR2+/+ ∆NC16A mice did not showed a significant difference in tumor 
progression (B) and tumor volume (C). IF staining showed skin∆NC16ACXCR2-/- mice 
still have both tumor infiltrating Ly6G+ and Ly6C+ immune cells inside the tumor isolated 
at 21 days post B16 injection (D).   
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In addition, the migration of MDSC from bone marrow to tumor has been 
proposed to be regulated by chemokines produced by the tumor with little specificity in 
the types of chemokines produced by different tumors (Kumar et al. 2016), which 
supports the possibility that even though CXCR2 plays a key role in PMN-MDSC 
migration in colitis-associated cancer (Katoh et al. 2013), it may not play the same role 
in the ∆NC16A mice. We also found there is an abundant Ly6C+ M-MDSCs in the 
tumors of NC16A/CXCR2 double deficient mice, which supports this possibility. It was 
reported that M-MDSCs  and the tumor associated macrophages (TAM) exhibit much 
higher immunosuppressive ability compared to PMN-MDSCs (Youn et al. 2008)(Youn et 
al. 2012a)(Condamine et al. 2015)(Gabrilovich and Nagaraj 2009). In conclusion, 
CXCR2 is not required for MDSC driven melanoma progression in ∆NC16A mice.   
 
Another important question awaiting future study is how MCs promote the 
migration of MDSCs in ∆NC16A mice.  Even though it had been reported that MCs 
promote the migration of MDSCs into the tumor site, its mechanism is still unclear (Yang 
et al. 2010). Our cytokine arrays showed that MC deficient ∆NC16A skin exhibits a 
significant reduction of three cytokines which had been reported to play a major role in 
MDSC recruitment and function into the tumor microenvironment (Kumar et al. 2016), 
which are CXCL1 and CCL2 (Figure 4.3). However, further studies are needed to 
explain how MCs are critical in MDSC infiltration in ∆NC16A mice.  
135 
 
 
Figure 4.3 Mast cells play a significant role in the concentration of CCL2 and CXCL1 in 
∆NC16A mice. A. Inflammatory cytokine array showed that mast cell deficient (MC-/-) 
skin∆NC16A mice exhibited a significant reduction in the chemokine CXCL1 and CCL2. B-C 
ELISA assay confirmed that MC-/- significant reduced the amount of CCL2 (B) and CXCL1 (C) in 
∆NC16A skin. Mast reconstitution of (+MC) restored the amount of CCL2 (B) and CXCL1 (C) in 
∆NC16A skin of MC -/-  mice. N=9, * p<0.05. 
 
4.4 Possible roles of BP180 in modulating the proinflammatory signaling pathway 
in keratinocytes, which leads to skin inflammation and melanoma progression 
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Our future study will focus on the mechanisms of how BP180 deficiency 
promotes the infiltrating of mast cells, which leads to MDSC promoted melanoma 
progression. Our hypothesis is that BP180 dysfunction promotes the secretion of mast 
cell chemoattracting chemokines. We currently found three major chemokines which are 
upregulated in ∆NC16A skin: CXCL1, CXCL2 and CCL2. CXCL1 and 2 bind to CXCR2; 
while CCL2 binds to the CCR2 receptor. CXCR2 is mostly related to neutrophil 
migration, but also reported to play a role in mast cell migration (Dahlin and Hallgren 
2015). CCR2 is mostly known as a mediator for monocyte/macrophage trafficking but 
there is also a role in mast cell migration in lung inflammation (Collington et al. 2010). 
So far, we still do not have enough evidence to suggest how BP180 deficiency in 
keratinocytes may trigger the influx of mast cells into skin through specific chemokines. 
In addition, stem cell factor (SCF) produced by basal keratinocytes plays a major role in 
MC migration and skin inflammation (Wang et al. 2017) and we do not observe MC 
influx in the NC16A/SCF receptor double deficient mice (TamCre-NC16AWsh). 
Therefore, it is possible that ∆NC16A upregulates SCF expression to attract MC influx 
into skin.   
 
The other remaining question is how does BP180 dysfunction upregulate the 
secretion of cytokines, which include TSLP and CXCL1. The only established role of 
BP180 is cell/ECM adhesion in skin basal keratinocytes in vivo. However, recent studies 
show that BP180 plays a role in modulation of NF-κB signal transduction through an 
unknown mechanism, which leads to the increased secretion of IL8 (the human 
homologue of mouse CXCL1/2) in vitro in response to LPS and TNFα stimulation (Van 
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den Bergh et al. 2012). Our current data shows that NF-κB inhibition significantly 
reduces the CXCL1 production from ∆NC16A keratinocytes (Figure 4.4). However, we 
are still unable to explain how ∆NC16A upregulates the NF-κB pathway, which leads to 
the secretion of inflammatory cytokines, such as CXCL1 and TSLP. 
 
Figure 4.4. Keratinocytes lacking NC16A promote the production of CXCL1 
through NF-κB pathway in vitro. ∆NC16A keratinocytes secrete a significantly 
increased CXCL1 four hours after 5 μg/ml LPS stimulation. In addition, the treatment of 
NF-κB inhibitor (Bay 11-7052, 5 μM) significantly reduced the CXCL1 secretion from 
LPS stimulated ∆NC16A keratinocytes. 
 
Lastly, it was also reported that BP180 dysfunction may upregulate the 
phosphorylation of FAK (Löffek et al. 2014). In addition, it was reported that mechanical 
stress may activate FAK/Src signaling, and then upregulate the downstream NF-κB 
pathway. Therefore, we hypothesize that ∆NC16A may lead to altered cell attachment 
and result in mechanical stress, which eventually upregulates FAK phosphorylation and 
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downstream Src and NF-κB signaling. We found FAK phosphorylation is significantly 
increased in LPS treated ∆NC16A keratinocytes (Figure 4.5).  When treated with FAK or 
Src inhibitors, the secretion of CXCL1 from LPS stimulated ∆NC16A keratinocytes is 
significantly reduced (Figure 4.6). These results support our hypothesis that FAK and 
Src may play an important role in the secretion of CXCL1 from ∆NC16A keratinocytes. 
Future studies are needed to elucidate how ∆NC16A affects FAK and Src signaling 
transduction which is upstream of inflammatory cytokines/chemokines.   
 
Figure 4.5. ∆NC16A significantly upregulates the phosphorylation of FAK in vitro. 
 
 
139 
 
Figure 4.6. FAK and Src inhibition significantly reduce the increased CXCL1 
production in ∆NC16A keratinocytes. ∆NC16A keratinocytes secrete a significantly 
increased CXCL1 four hours after 5 μg/ml LPS stimulation. In addition, the treatment of 
Src inhibitor (PP2, 5 μM) or FAK inhibitor (PF57328, 5 μM) significantly reduced the 
CXCL1 secretion from LPS stimulated ∆NC16A keratinocytes to the level of the 
∆NC16A cells treated with NF-κB inhibitor (Bay 11-7052, 5 μM). 
 
4.5 Proposed future experiments 
Two independent experiments I would like to propose to answer some of the 
questions and directions I raised in Chapter 4 (Figure 4.7). First experiment aims to test 
the following hypothesis: the skin inflammation triggered by BP180 dysfunction is 
depend on the upregulation of NF-κB in basal keratinocytes. Second experiment aims to 
answer another hypothesis: BP180 dysfunction upregulates the secretion of stem cell 
factor (SCF) from skin basal keratinocytes, which leads to increased mast cells influx in 
skin and skin inflammation.  
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Figure 4.7 Two future experiments I proposed. Proposed Experiment #1 focuses on 
whether NF-κB plays a vital role in the skin inflammation triggered by BP180 
dysfunction. Proposed Experiment #2 focuses on whether SCF plays a vital role in the 
mast cells accumulation and skin inflammation triggered by BP180 dysfunction. 
Proposed experiment #1 
To investigate whether NF-κB plays a key role in the production of 
proinflammatory cytokine from BP180 dysfunctional basal keratinocyte in vivo, we 
proposed to generate NC16A/NF-κB conditional double knockout mice by crossing the 
RelACKO/CKO  mice (Ijaz et al. 2016) with our hNC16A mice. The RelACKO/CKO  mice are 
fertile, do not display any developmental defects and can be crossed with Cre-
expressing mice to delete RelA in a temporal, tissue-specific manner (Ijaz et al. 2016). 
We can generate a tamoxifen inducible NC16A/RelA by crossing them with the 
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TamCre/∆NC16A mice (termed NC16A/RelADKO). In theory, NC16A/RelADKO should 
be fertile and do not display any defect. When painted with tamoxifen on its skin, Cre 
recombinase will delete both NC16A and RelA and leads to the dysfunction of both 
BP180 and NF-κB in local skin. To narrow down to basal keratinocytes, we can also 
cross the RelACKO/CKO  mice with K14cre/∆NC16A mice to generate basal keratinocyte 
conditional BP180/NF-κB double knockout mice. We can use this mice to test whether 
NF-κB plays a key role in the skin inflammation and increased melanoma progression 
on BP180 dysfunctional mice. If my hypothesis is supported, skin inflammation and B16 
melanoma progression will be significantly decreased in the NC16A/RelADKO 
compared to the ∆NC16A mice. 
Proposed experiment #2 
SCF plays a key role in maintaining the population of mast cells in peripheral 
tissues (Halova et al. 2012). Mice carrying spontaneous loss-of-function mutations at 
the SCF receptor c-kit, exhibit a marked reduction in c-kit tyrosine kinase-dependent 
signaling, resulting in disrupted normal mast cell development and survival, and 
therefore mast cell function (Grimbaldeston et al. 2005). We found there is a significant 
increase in the amount of SCF in the skin of both skin∆NC16A and K14cre/∆NC16A 
mice (Figure 4.8). Therefore, I hypothesize that BP180 dysfunction may promote the 
production of SCF from basal keratinocytes, which leads to the increased amount mast 
cells in skin. To test our hypothesis, we propose to generate a NC16A/SCF double 
knockout mouse model by crossing Scffl/fl mice containing floxed Scf alleles (Wang et al. 
2017) with hNC16A mice. The Scffl/fl  mice are fertile, do not display any developmental 
defects and can be crossed with Cre-expressing mice to delete SCF in a temporal, 
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tissue-specific manner (Wang et al. 2017). We can generate a tamoxifen inducible 
NC16A/SCF by crossing them with the TamCre/∆NC16A mice (termed 
NC16A/SCFDKO). In theory, NC16A/SCFDKO should be fertile and do not display any 
defect. When painted with tamoxifen on its skin, Cre recombinase will delete both DNA 
sequence encoding NC16A and SCF in local skin. To narrow down to basal 
keratinocytes, we can also cross the Scffl/fl  mice with K14cre/∆NC16A mice to generate 
basal keratinocyte conditional BP180/SCF double knockout mice. We can use this mice 
to test whether SCF plays a key role in the mast cells accumulation in the skin of BP180 
dysfunctional mice, which eventually result in skin inflammation and increased 
melanoma progression. If my hypothesis is supported, skin inflammation and B16 
melanoma progression will be significantly decreased in the NC16A/SCFDKO 
compared to the ∆NC16A mice. 
 
Figure 4.8. NF-κB inhibitor ammonium pyrrolidinedithiocarbamate (PDTC) 
significantly reduces the level of stem cell factor (SCF) in the skin of  
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∆NC16A mice. A. ELISA results showed that K14Cre/∆NC16A mice with daily PDTC 
injection showed a significantly reduced level of chemokines SCF in to the mice with 
PBS injection. n=15 for PBS injected, n=6 for PDTC injected, * p<0.05. B. 
TamCre/∆NC16A mice with skin local tamoxifen treatment (14 days after 10mg/ml of 
Tamoxifen painted on both ears) were used as skin∆NC16A. ELISA results also showed 
that skin∆NC16A mice with daily PDTC injection showed a significantly reduced level of 
chemokines SCF in to the mice with PBS injection. n=8 for PBS injected, n=11 for 
PDTC injected, * p<0.05.  
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